<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SAPHRIS- asenapine maleateÂ tabletÂ </strong><br>Forest Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SAPHRIS (asenapine) sublingual tablets safely and effectively. See full prescribing information for SAPHRIS.<br>SAPHRIS<span class="Sup">Â®</span> (asenapine) sublingual tablets<br>Initial U.S. Approval: 2009
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. SAPHRIS is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (<a href="#s16">5.1</a>, <a href="#s17">5.2</a>)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" width="83.550%">
<col align="left" width="16.450%">
<tbody class="Headless">
<tr>
<td align="justify" valign="top">Boxed Warning
</td>
<td align="right" valign="top">10/2014
</td>
</tr>
<tr>
<td align="justify" valign="top">Indications and Usage (<a href="#s4">1</a>)
</td>
<td align="right" valign="top">03/2015
</td>
</tr>
<tr>
<td align="justify" valign="top">Dosage and Administration (<a href="#s5">2</a>)
</td>
<td align="right" valign="top">03/2015
</td>
</tr>
<tr>
<td align="justify" valign="top">Contraindications (<a href="#s14">4</a>)
</td>
<td align="right" valign="top">03/2015
</td>
</tr>
<tr>
<td align="left" valign="top">Warnings and Precautions (<a href="#s15">5</a>)
</td>
<td align="right" valign="top">03/2015
</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. SAPHRIS is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (<a href="#s16">5.1</a>, <a href="#s17">5.2</a>)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">SAPHRIS is an atypical antipsychotic indicated for (<a href="#s4">1</a>):
 </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</li>
<li>Acute treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> as monotherapy or adjunctive treatment to lithium or valproate
</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<table width="100%">
<col align="left" width="28.575%">
<col align="left" width="21.425%">
<col align="left" width="28.575%">
<col align="left" width="21.425%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Starting Dose</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Recommended Dose</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Maximum</span><br><span class="Bold">Dose</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> â€“ acute treatment in adults (<a href="#s7">2.2</a>)
</td>
<td class="Botrule Rrule" align="center" valign="top">5 mg sublingually twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">5 mg sublingually twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">10 mg sublingually twice daily
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> â€“ maintenance treatment in adults (<a href="#s7">2.2</a>)
</td>
<td class="Botrule Rrule" align="center" valign="top">5 mg sublingually twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">5-10 mg sublingually twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">10 mg sublingually twice daily
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> â€“ adults: monotherapy (<a href="#s8">2.3</a>)
</td>
<td class="Botrule Rrule" align="center" valign="top">10 mg sublingually twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">5-10 mg sublingually twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">10 mg sublingually twice daily
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> â€“pediatric patients (10 to 17 years): monotherapy (<a href="#s8">2.3</a>)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.5 mg sublingually twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">2.5-10 mg sublingually twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">10 mg sublingually twice daily
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> â€“ adults: as an adjunct to lithium or valproate (<a href="#s8">2.3</a>)
</td>
<td class="Botrule Rrule" align="center" valign="top">5 mg sublingually twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">5-10 mg sublingually twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">10 mg sublingually twice daily
</td>
</tr>
</tbody>
</table>
<ul class="Disc"><li>Do not swallow tablet. SAPHRIS sublingual tablets should be placed under the tongue and left to dissolve completely. The tablet will dissolve in saliva within seconds. Eating and drinking should be avoided for 10 minutes after administration. (<a href="#s6">2.1</a>, <a href="#s114">17</a>)
</li></ul>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Sublingual tablets, black cherry flavor: 2.5 mg, 5 mg and 10 mg (<a href="#s13">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C). (<a href="#s82">8.7</a>, <a href="#s94">12.3</a>)
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to SAPHRIS (asenapine), or to any components in the formulation. (<a href="#s14">4</a>, <a href="#s27">5.6</a>, <a href="#s114">17</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Cerebrovascular Adverse Events:</span> An increased incidence of cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack) has been seen in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related psychoses treated with atypical antipsychotic drugs. (<a href="#s17">5.2</a>)
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>:</span> Manage with immediate discontinuation and close monitoring. (<a href="#s18">5.3</a>)
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>:</span> Discontinue if clinically appropriate. (<a href="#s19">5.4</a>)
</li>
<li>
<span class="Italics">Metabolic Changes:</span> Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. (<a href="#s20">5.5</a>)<ul class="Disc">
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus:</span> Monitor patients for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Monitor glucose regularly in patients with, and at risk for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. (<a href="#s20">5.5</a>)
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>:</span> Undesirable alterations have been observed in patients treated with atypical antipsychotics. (<a href="#s20">5.5</a>)
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span>: Patients should receive regular monitoring of weight. (<a href="#s20">5.5</a>)
</li>
</ul>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, have been observed. (<a href="#s27">5.6</a>)
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, and Other Hemodynamic Effects:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> may occur, especially early in treatment. Use with caution in patients with known cardiovascular or cerebrovascular disease, and in antipsychotic-naÃ¯ve patients. (<a href="#s28">5.7</a>)
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></span> have been reported with antipsychotics. Patients with a pre-existing low white blood cell count (WBC) or a history of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and SAPHRIS should be discontinued at the first sign of a decline in WBC in the absence of other causative factors. (<a href="#s29">5.8</a>)
</li>
<li>
<span class="Italics">QT Prolongation:</span> Increases in QT interval; avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval. (<a href="#s30">5.9</a>)
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>:</span> Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. (<a href="#s32">5.11</a>)
</li>
<li>
<span class="Italics">Potential for Cognitive and Motor Impairment:</span> Use caution when operating machinery. (<a href="#s33">5.12</a>)
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>:</span> The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder. Closely supervise high-risk patients. (<a href="#s35">5.14</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Commonly observed adverse reactions (incidence â‰¥5% and at least twice that for placebo) were (<a href="#s39">6.1</a>):
 </p>
<ul class="Disc">
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> Adults:</span> <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.
</li>
<li>
<span class="Italics">Bipolar Disorder Adults (Monotherapy):</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> other than <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, increased weight.
</li>
<li>
<span class="Italics">Bipolar Disorder Pediatric Patients (Monotherapy):</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, increased weight.
</li>
<li>
<span class="Italics">Bipolar Disorder Adults (Adjunctive):</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>.
</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Forest Laboratories, LLC. at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Antihypertensive Drugs: SAPHRIS may cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (<a href="#s28">5.7</a>, <a href="#s64">7.1</a>, <a href="#s94">12.3</a>)
</li>
<li>Paroxetine (CYP2D6 substrate and inhibitor): Reduce paroxetine by half when used in combination with SAPHRIS. (<a href="#s64">7.1</a>, <a href="#s94">12.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Pregnancy:</span> May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. (<a href="#s67">8.1</a>)
</li>
<li>
<span class="Italics">Pediatric Use:</span> Safety and efficacy in the treatment of bipolar disorder in patients less than 10 years of age, and patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> ages less than 12 years have not been evaluated. (<a href="#s76">8.4</a>)
</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span>
</a></h1>
<h1><a href="#section-1" class="toc"><span class="XmChange"></span>1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc"><span class="XmChange"></span>2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc"><span class="XmChange"></span>2.1 Administration Instructions
</a></h2>
<h2><a href="#section-2.2" class="toc"><span class="XmChange"></span>2.2 <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</a></h2>
<h2><a href="#section-2.3" class="toc"><span class="XmChange"></span>2.3 <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc"><span class="XmChange"></span>4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc"><span class="XmChange"></span>5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="XmChange"></span>5.1 Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>
</a></h2>
<h2><a href="#section-5.2" class="toc"><span class="XmChange"></span>5.2 Cerebrovascular Adverse Events, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, In Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>
</a></h2>
<h2><a href="#section-5.3" class="toc"><span class="XmChange"></span>5.3 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>
</a></h2>
<h2><a href="#section-5.4" class="toc"><span class="XmChange"></span>5.4 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>
</a></h2>
<h2><a href="#section-5.5" class="toc"><span class="XmChange"></span>5.5 Metabolic Changes
</a></h2>
<h2><a href="#section-5.6" class="toc"><span class="XmChange"></span>5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</a></h2>
<h2><a href="#section-5.7" class="toc"><span class="XmChange"></span>5.7 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, and Other Hemodynamic Effects
</a></h2>
<h2><a href="#section-5.8" class="toc"><span class="XmChange"></span>5.8 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>
</a></h2>
<h2><a href="#section-5.9" class="toc"><span class="XmChange"></span>5.9 QT Prolongation
</a></h2>
<h2><a href="#section-5.10" class="toc"><span class="XmChange"></span>5.10 <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span>
</a></h2>
<h2><a href="#section-5.11" class="toc"><span class="XmChange"></span>5.11 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</a></h2>
<h2><a href="#section-5.12" class="toc"><span class="XmChange"></span>5.12 Potential for Cognitive and Motor Impairment
</a></h2>
<h2><a href="#section-5.13" class="toc"><span class="XmChange"></span>5.13 Body Temperature Regulation
</a></h2>
<h2><a href="#section-5.14" class="toc"><span class="XmChange"></span>5.14 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>
</a></h2>
<h2><a href="#section-5.15" class="toc"><span class="XmChange"></span>5.15 <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>
</a></h2>
<h2><a href="#section-5.16" class="toc"><span class="XmChange"></span>5.16 Use in Patients with Concomitant Illness
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs Having Clinically Important Drug Interactions with SAPHRIS
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs Having No Clinically Important Interactions with SAPHRIS
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Lactation
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Other Specific Populations
</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance
</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse
</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</a></h2>
<h2><a href="#section-14.2" class="toc">14.2 Bipolar Disorder
</a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s3"></a><a name="section-1"></a><p></p>
<h1>WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span>
</h1>
<p class="First"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. SAPHRIS</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">(asenapine) is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>
</span><span class="Bold Italics">[see Warnings and Precautions (<a href="#s16">5.1</a>, <a href="#s17">5.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s4"></a><a name="section-1"></a><p></p>
<h1 style="border-left:1px solid;">
<span class="XmChange"></span>1 INDICATIONS AND USAGE
</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>SAPHRIS is indicated for:
</p>
<ul class="Disc">
<li style="border-left:1px solid;">
<span class="XmChange"></span><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> [see Clinical Studies (<a href="#s108">14.1</a>)]
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>Acute treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I disorder</span> as monotherapy or adjunctive treatment to lithium or valproate [see Clinical Studies (<a href="#s109">14.2</a>)]
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s5"></a><a name="section-2"></a><p></p>
<h1 style="border-left:1px solid;">
<span class="XmChange"></span>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.1"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>2.1 Administration Instructions
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>SAPHRIS is a sublingual tablet. To ensure optimal absorption, patients should be instructed to place the tablet under the tongue and allow it to dissolve completely. The tablet will dissolve in saliva within seconds. SAPHRIS sublingual tablets should not be split, crushed, chewed, or swallowed <span class="Italics">[see Clinical Pharmacology (<a href="#s94">12.3</a>)]</span>. Patients should be instructed to not eat or drink for 10 minutes after administration <span class="Italics">[see Clinical Pharmacology (<a href="#s94">12.3</a>) and Patient Counseling Information (<a href="#s114">17</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.2"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>2.2 <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>The recommended dose of SAPHRIS is 5 mg given twice daily.  In short term controlled trials, there was no suggestion of added benefit with a 10 mg twice daily dose, but there was a clear increase in certain adverse reactions. If tolerated, daily dosage can be increased to 10 mg twice daily after one week. The safety of doses above 10 mg twice daily has not been evaluated in clinical studies <span class="Italics">[see Clinical Studies (<a href="#s108">14.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.3"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>2.3 <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.3.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Bold Italics">Acute Treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> or Mixed Episodes:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.3.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics Underline">Monotherapy in Adults</span>: The recommended starting dose of SAPHRIS is 10 mg twice daily. The dose can be decreased to 5 mg twice daily if warranted by adverse effects. The safety of doses above 10 mg twice daily has not been evaluated in clinical trials <span class="Italics">[see Clinical Studies (<a href="#s109">14.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.3.3"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics Underline">Monotherapy in Pediatric Patients:</span> The recommended dose of SAPHRIS is 2.5 mg to 10 mg twice daily in pediatric patients 10 to 17 years of age, and dose may be adjusted for individual response and tolerability. The starting dose of SAPHRIS is 2.5 mg twice daily. After 3 days, the dose can be increased to 5 mg twice daily, and from 5 mg to 10 mg twice daily after 3 additional days. Pediatric patients aged 10 to 17 years appear to be more sensitive to <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span> with initial dosing with SAPHRIS when the recommended escalation schedule is not followed <span class="Italics">[see Use in Specific Populations (<a href="#s76">8.4</a>)]</span>. The safety of doses greater than 10 mg twice daily has not been evaluated in clinical trials <span class="Italics">[see Use in Specific Populations (<a href="#s76">8.4</a>) and Clinical Pharmacology (<a href="#s94">12.3</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.3.4"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics Underline">Adjunctive Therapy in Adults:</span> The recommended starting dose of SAPHRIS is 5 mg twice daily when administered as adjunctive therapy with either lithium or valproate. Depending on the clinical response and tolerability in the individual patient, the dose can be increased to 10 mg twice daily. The safety of doses above 10 mg twice daily as adjunctive therapy with lithium or valproate has not been evaluated in clinical trials.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>If SAPHRIS is used for extended periods in bipolar disorder, the health care provider should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s13"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<ul class="Disc">
<li>SAPHRIS 2.5 mg tablets, black cherry flavor, are round, white to off-white sublingual tablets, with a hexagon on one side.
</li>
<li>SAPHRIS 5 mg tablets, black cherry flavor, are round, white to off-white sublingual tablets, with â€œ5â€? on one side within a circle.
</li>
<li>SAPHRIS 10 mg tablets, black cherry flavor, are round, white to off-white sublingual tablets, with â€œ10â€? on one side within a circle.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s14"></a><a name="section-4"></a><p></p>
<h1 style="border-left:1px solid;">
<span class="XmChange"></span>4 CONTRAINDICATIONS
</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>SAPHRIS is contraindicated in patients with:
</p>
<ul class="Disc">
<li style="border-left:1px solid;">
<span class="XmChange"></span>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) <span class="Italics">[see Specific Populations (<a href="#s82">8.7</a>), Clinical Pharmacology (<a href="#s94">12.3</a>)]</span>.
</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>A history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to asenapine. Reactions have included <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> <span class="Italics">[see Warnings and Precautions (<a href="#s27">5.6</a>), Adverse Reactions (<a href="#s38">6</a>) and Patient Counseling Information (<a href="#s114">17</a>)]</span>.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s15"></a><a name="section-5"></a><p></p>
<h1 style="border-left:1px solid;">
<span class="XmChange"></span>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.1"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.1 Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in the drug-treated patients of between 1.6 to 1.7 times that  seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. SAPHRIS is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see <a href="#s3">Boxed Warning</a> and Warnings and Precautions (<a href="#s17">5.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.2"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.2 Cerebrovascular Adverse Events, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, In Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, there was a higher incidence of cerebrovascular adverse reactions (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span> and <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span>) including fatalities compared to placebo-treated subjects. SAPHRIS is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see also <a href="#s3">Boxed Warning</a> and Warnings and Precautions (<a href="#s16">5.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.3"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.3 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with administration of antipsychotic drugs, including SAPHRIS. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> (<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>), and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The diagnostic evaluation of patients with this syndrome is complicated. It is important to exclude cases where the clinical presentation includes both serious medical illness (e.g. <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system pathology.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.4"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.4 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>A syndrome of potentially irreversible, involuntary, dyskinetic movements can develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> (TD) is unknown.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Given these considerations, SAPHRIS should be prescribed in a manner that is most likely to minimize the occurrence of TD. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>If signs and symptoms of TD appear in a patient on SAPHRIS, drug discontinuation should be considered. However, some patients may require treatment with SAPHRIS despite the presence of the syndrome.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.5"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.5 Metabolic Changes
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.5.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients treated with atypical antipsychotics. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events in patients treated with the atypical antipsychotics included in these studies. Precise risk estimates for <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events in patients treated with atypical antipsychotics are not available.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the antipsychotic drug.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">Adult Patients:</span> Pooled data from the short-term placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials are presented in <span class="Bold"><a href="#t1">Table 1</a>.</span></p>
<a name="t1"></a><table width="100%">
<caption><span>TABLE 1: Changes in Fasting Glucose in Adult Patients
</span></caption>
<col align="left" width="19.010%">
<col align="left" width="12.700%">
<col align="left" width="10%">
<col align="left" width="13.280%">
<col align="left" width="10%">
<col align="left" width="13.030%">
<col align="left" width="13.310%">
<col align="left" width="13.790%">
<col align="left" width="10%">
<col align="left" width="13.790%">
<tfoot>
<tr class="First"><td align="left" colspan="10" valign="top"><p class="First Footnote">N* = Number of patients who had assessments at both Baseline and Endpoint.
</p></td></tr>
<tr><td align="left" colspan="10" valign="top"><p class="First Footnote">N** = Number of patients at risk at Baseline with assessments at both Baseline and Endpoint.
</p></td></tr>
<tr><td align="left" colspan="10" valign="top"><p class="First Footnote"><span class="Sup">Â§</span> Includes patients treated with flexible dose of SAPHRIS 5 or 10 mg twice daily (N=90).
</p></td></tr>
<tr class="Last"><td align="left" colspan="10" valign="top"><p class="First Footnote"><span class="Sup">â€ </span>SAPHRIS 5 mg or 10 mg twice daily with flexible dosing.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="6" valign="top"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (6-weeks)
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top">Bipolar (3-weeks)
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">
<br><br>Placebo<br>
</td>
<td class="Botrule Rrule" align="center" colspan="5" valign="top">SAPHRIS
</td>
<td class="Botrule Rrule" align="center" colspan="2" rowspan="2" valign="top">
<br><br>Placebo<br>
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">SAPHRIS<br>5 or 10 mg<br>twice daily<span class="Sup">â€ </span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">5 mg<br>twice daily<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">10 mg<br>twice daily<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">5 or 10 mg<br>twice daily<span class="Sup">Â§</span><br>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="10" valign="top">Mean Change from Baseline in Fasting Glucose at Endpoint
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â 
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Change from Baseline (mg/dL) (N*)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">-0.2<br>(232)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.8<br>(158)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">1.1<br>(153)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.2<br>(377)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">-0.6<br>(89)
</td>
<td class="Botrule Rrule" align="center" valign="top">-0.6<br>(156)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="10" valign="top">Proportion of Patients  with Shifts from Baseline to Endpoint
</td></tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">Normal to High<br>&lt;100 to â‰¥126 mg/dL
</td>
<td class="Rrule" align="center" colspan="2" valign="top">4.1%
</td>
<td class="Rrule" align="center" valign="top">4.5%
</td>
<td class="Rrule" align="center" colspan="2" valign="top">4.5%
</td>
<td class="Rrule" align="center" valign="top">5.0%
</td>
<td class="Rrule" align="center" colspan="2" valign="top">3.3%
</td>
<td class="Rrule" align="center" valign="top">2.7%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">(n/N**)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">(7/170)
</td>
<td class="Botrule Rrule" align="center" valign="top">(5/111)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">(5/111)
</td>
<td class="Botrule Rrule" align="center" valign="top">(13/262)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">(2/61)
</td>
<td class="Botrule Rrule" align="center" valign="top">(3/111)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="middle">Borderline to High<br>â‰¥100 and &lt;126<br>to â‰¥126 mg/dL
</td>
<td class="Rrule" align="center" colspan="2" valign="middle">5.9%
</td>
<td class="Rrule" align="center" valign="middle">6.8%
</td>
<td class="Rrule" align="center" colspan="2" valign="middle">6.3%
</td>
<td class="Rrule" align="center" valign="middle">10.5%
</td>
<td class="Rrule" align="center" colspan="2" valign="middle">0.0%
</td>
<td class="Rrule" align="center" valign="middle">11.4%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">(n/N**)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">(3/51)
</td>
<td class="Botrule Rrule" align="center" valign="middle">(3/44)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">(2/32)
</td>
<td class="Botrule Rrule" align="center" valign="middle">(10/95)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">(0/23)
</td>
<td class="Botrule Rrule" align="center" valign="middle">(4/35)
</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange"></span>In a 52-week, double-blind, comparator-controlled trial that included primarily patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean increase from baseline of fasting glucose was 2.4 mg/dL.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">Pediatric Patients:</span> Data from the short-term, placebo-controlled trial in pediatric patients with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> are shown in <span class="Bold"><a href="#t2">Table 2</a></span>.
</p>
<a name="t2"></a><table width="100%">
<caption><span>TABLE 2: Changes in Fasting Glucose in Pediatric Subjects
</span></caption>
<col align="left" width="17.676%">
<col align="left" width="20.836%">
<col align="left" width="23.955%">
<col align="left" width="22.955%">
<col align="left" width="14.577%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><span class="XmChange"></span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (3-weeks)
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">
<span class="XmChange"></span><br><br>Placebo<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">SAPHRIS<br>2.5 mg<br>twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">SAPHRIS<br>5 mg<br>twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">SAPHRIS<br>10 mg<br>twice daily
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="XmChange"></span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top">Mean Change from Baseline in Fasting Glucose at Endpoint
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="XmChange"></span>Change from Baseline (mg/dL) (N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">-2.24<br>(56)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.43<br>(51)
</td>
<td class="Botrule Rrule" align="center" valign="top">-0.45<br>(57)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.34<br>(52)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="XmChange"></span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top">Proportion of Subjects with Shifts from Baseline to Endpoint
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">
<span class="XmChange"></span>Normal to High&gt;45 &amp; &lt; 100 to â‰¥126 mg/dL
</td>
<td class="Rrule" align="center" valign="top">0%
</td>
<td class="Rrule" align="center" valign="top">0%
</td>
<td class="Rrule" align="center" valign="top">1.8%
</td>
<td class="Rrule" align="center" valign="top">0%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<span class="XmChange"></span>(n/N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">(0/56)
</td>
<td class="Botrule Rrule" align="center" valign="top">(0/51)
</td>
<td class="Botrule Rrule" align="center" valign="top">(1/57)
</td>
<td class="Botrule Rrule" align="center" valign="top">(0/52)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.5.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">Adult Patients:</span> Pooled data from the short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials are presented in <span class="Bold"><a href="#t3">Table 3</a>.</span></p>
<a name="t3"></a><table width="100%">
<caption><span>TABLE 3: Changes in Lipids in Adult Patients
</span></caption>
<col align="left" width="17.943%">
<col align="left" width="13.600%">
<col align="left" width="14.357%">
<col align="left" width="14.357%">
<col align="left" width="12.300%">
<col align="left" width="13.743%">
<col align="left" width="13.700%">
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote">N* = Number of subjects who had assessments at both Baseline and Endpoint.
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">Â§</span> Includes subjects treated with flexible dose of SAPHRIS 5 or 10 mg twice daily (N=90).
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">â€ </span>SAPHRIS 5 mg or 10 mg twice daily with flexible dosing.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (6-weeks)
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">Bipolar (3-weeks)
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle">Placebo
</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">SAPHRIS
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle">Placebo
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">SAPHRIS<br>5 or 10 mg<br>twice daily<span class="Sup">â€ </span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">5 mg<br>twice daily<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">10 mg<br>twice daily<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">5 or 10 mg<br>twice daily<span class="Sup">Â§</span><br>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="7" valign="top">Mean Change from Baseline (mg/dL)
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<br>Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>(N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">-2.2<br>(351)
</td>
<td class="Botrule Rrule" align="center" valign="top">-2.4<br>(258)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.3<br>(199)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.4<br>(539)
</td>
<td class="Botrule Rrule" align="center" valign="top">-1.5<br>(163)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.1<br>(322)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<br>LDL (N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.1<br>(285)
</td>
<td class="Botrule Rrule" align="center" valign="top">-0.2<br>(195)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.6<br>(195)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.3<br>(465)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.9<br>(158)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.6<br>(304)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<br>HDL (N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.5<br>(290)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.4<br>(199)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.0<br>(199)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.5<br>(480)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.0<br>(163)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.9<br>(322)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Fasting triglycerides (N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">-7.6<br>(233)
</td>
<td class="Botrule Rrule" align="center" valign="top">-1.9<br>(159)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.1<br>(154)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.8<br>(380)
</td>
<td class="Botrule Rrule" align="center" valign="top">-17.9<br>(129)
</td>
<td class="Botrule Rrule" align="center" valign="top">-3.5<br>(237)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="7" valign="top">Proportion of Patients  with Shifts from Baseline to Endpoint
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span><br>Normal to High<br>&lt;200 to â‰¥240<br>(mg/dL) (n/N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.3%<br>(3/225)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.6%<br>(1/161)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.2%<br>(3/134)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.7%<br>(6/343)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.1%<br>(1/95)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.5%<br>(5/204)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">LDL<br>Normal to High<br>&lt;100 to â‰¥160<br>(mg/dL) (n/N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.7%<br>(2/117)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.0%<br>(0/80)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.2%<br>(1/86)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.0%<br>(2/196)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.9%<br>(1/53)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.0%<br>(0/141)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">HDL<br>Normal to Low<br>â‰¥40 to &lt;40 (mg/dL) (n/N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">10.7%<br>(21/196)
</td>
<td class="Botrule Rrule" align="center" valign="top">13.3%<br>(18/135)
</td>
<td class="Botrule Rrule" align="center" valign="top">14.7%<br>(20/136)
</td>
<td class="Botrule Rrule" align="center" valign="top">14.0%<br>(45/322)
</td>
<td class="Botrule Rrule" align="center" valign="top">7.4%<br>(9/122)
</td>
<td class="Botrule Rrule" align="center" valign="top">8.7%<br>(21/242)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Fasting triglycerides<br>Normal to High<br>&lt;150 to â‰¥200 (mg/dL) (n/N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.4%<br>(4/167)
</td>
<td class="Botrule Rrule" align="center" valign="top">7.0%<br>(8/115)
</td>
<td class="Botrule Rrule" align="center" valign="top">8.3%<br>(9/108)
</td>
<td class="Botrule Rrule" align="center" valign="top">7.7%<br>(20/260)
</td>
<td class="Botrule Rrule" align="center" valign="top">5.1%<br>(4/78)
</td>
<td class="Botrule Rrule" align="center" valign="top">7.4%<br>(11/148)
</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange"></span>In short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, the proportion of patients with total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> elevations â‰¥240 mg/dL (at Endpoint) was 8.3% for SAPHRIS-treated patients versus 7% for placebo-treated patients. The proportion of patients with elevations in triglycerides â‰¥200 mg/dL (at Endpoint) was 13.2% for SAPHRIS-treated patients versus 10.5% for placebo-treated patients. In short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, the proportion of patients with total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> elevations â‰¥240 mg/dL (at Endpoint) was 8.7% for SAPHRIS-treated patients versus 8.6% for placebo-treated patients. The proportion of patients with elevations in triglycerides â‰¥200 mg/dL (at Endpoint) was 15.2% for SAPHRIS-treated patients versus 11.4% for placebo-treated patients.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>In a 52-week, double-blind, comparator-controlled trial that included primarily patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean decrease from baseline of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> was 6 mg/dL and the mean decrease from baseline of fasting triglycerides was 9.8 mg/dL.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.5.3"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">Pediatric Patients:</span> Data from the short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trial are presented in <span class="Bold"><a href="#t4">Table 4</a></span>.
</p>
<a name="t4"></a><table width="100%">
<caption><span>TABLE 4: Changes in Fasting Lipids in Pediatric Subjects
</span></caption>
<col align="left" width="30.126%">
<col align="left" width="14.963%">
<col align="left" width="18.304%">
<col align="left" width="18.304%">
<col align="left" width="18.304%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">N* = Number of patients who had assessments at both Baseline and Endpoint
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="justify" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (3-weeks)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="justify" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">
<br><br>Placebo<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">SAPHRIS<br>2.5 mg<br>twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">SAPHRIS<br>5 mg<br>twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">SAPHRIS<br>10 mg<br>twice daily
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="5" valign="top">Mean Change from Baseline (mg/dL)
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Total fasting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">-2.3<br>(57)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.7<br>(50)
</td>
<td class="Botrule Rrule" align="center" valign="top">7.2<br>(57)
</td>
<td class="Botrule Rrule" align="center" valign="top">9.3<br>(52)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Fasting LDL<br>(N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">-2.5<br>(57)
</td>
<td class="Botrule Rrule" align="center" valign="top">-0.2<br>(50)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.0<br>(57)
</td>
<td class="Botrule Rrule" align="center" valign="top">4.9<br>(51)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Fasting HDL<br>(N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.6<br>(57)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.3<br>(50)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.5<br>(57)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.7<br>(52)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Fasting triglycerides (N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">-6.6<br>(57)
</td>
<td class="Botrule Rrule" align="center" valign="top">8.7<br>(50)
</td>
<td class="Botrule Rrule" align="center" valign="top">13.4<br>(57)
</td>
<td class="Botrule Rrule" align="center" valign="top">14.7<br>(52)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="5" valign="top">Proportion of Subjects with Shifts from Baseline to Endpoint
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Total fasting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span><br>Normal to High<br>&lt;170 to &gt;=200<br>(mg/dL)<br>(n/N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.8%<br>(1/57)
</td>
<td class="Botrule Rrule" align="center" valign="top">0%<br>(0/50)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.8%<br>(1/57)
</td>
<td class="Botrule Rrule" align="center" valign="top">0%<br>(0/52)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Fasting LDL<br>Normal to High<br>&lt;110 to &gt;=130<br>(n/N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.8%<br>(1/57)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.0%<br>(1/50)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.8%<br>(1/57)
</td>
<td class="Botrule Rrule" align="center" valign="top">0%<br>(0/51)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Fasting HDL<br>Normal to Low<br>â‰¥40 to &lt;40 (mg/dL)<br>(n/N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.5%<br>(2/57)
</td>
<td class="Botrule Rrule" align="center" valign="top">6.0%<br>(3/50)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.5%<br>(2/57)
</td>
<td class="Botrule Rrule" align="center" valign="top">9.6%<br>(5/52)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Fasting triglycerides<br>Normal to High<br>&lt;150 to â‰¥200 (mg/dL)<br>(n/N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">0%<br>(0/57)
</td>
<td class="Botrule Rrule" align="center" valign="top">4.0%<br>(2/50)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.5%<br>(2/57)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.9%<br>(1/52)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-5.5.4"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Increases in weight have been observed in pre-marketing clinical trials with SAPHRIS. Patients receiving SAPHRIS should receive regular monitoring of weight <span class="Italics">[see Patient Counseling Information (<a href="#s114">17</a>)]</span>.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">Adult Patients:</span> Pooled data on mean changes in body weight and the proportion of subjects meeting a <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> criterion of â‰¥7% of body weight from the short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials are presented in <span class="Bold"><a href="#t5">Table 5</a>.</span></p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5: Change in Body Weight in Adult Patients from Baseline
</span></caption>
<col align="left" width="18.969%">
<col align="left" width="13.741%">
<col align="left" width="12.970%">
<col align="left" width="14.041%">
<col align="left" width="14.041%">
<col align="left" width="12.970%">
<col align="left" width="13.270%">
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote">N* = Number of subjects who had assessments at both Baseline and Endpoint.
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">Â§</span> Includes subjects treated with flexible dose of SAPHRIS 5 or 10 mg twice daily (N=90).
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">â€ </span>SAPHRIS 5 mg or 10 mg twice daily with flexible dosing.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (6-weeks)
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">Bipolar (3-weeks)
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">
<br><br>Placebo<br>
</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">SAPHRIS
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">
<br><br>Placebo<br>
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">SAPHRIS<br>5 or 10 mg<br>twice daily<span class="Sup">â€ </span><br><br>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">5 mg<br>twice daily<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">10 mg<br>twice daily<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">5 or 10 mg<br>twice daily<span class="Sup">Â§</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Change from Baseline (kg) (N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.0<br>(348)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.0<br>(251)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.9<br>(200)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.1<br>(532)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.2<br>(171)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.3<br>(336)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="7" valign="top">Proportion of Patients with a â‰¥7% Increase in Body Weight
</td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">% with â‰¥7% increase in body weight
</td>
<td class="Botrule Rrule" align="center" valign="top">1.6%
</td>
<td class="Botrule Rrule" align="center" valign="top">4.4%
</td>
<td class="Botrule Rrule" align="center" valign="top">4.8%
</td>
<td class="Botrule Rrule" align="center" valign="top">4.9%
</td>
<td class="Botrule Rrule" align="center" valign="top">0.5%
</td>
<td class="Botrule Rrule" align="center" valign="top">5.8%
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.5.5"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">Adult Patients:</span> In a 52-week, double-blind, comparator-controlled adult trial that included primarily patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> from baseline was 0.9 kg. The proportion of patients with a â‰¥7% increase in body weight (at Endpoint) was 14.7%. <a href="#t5">Table 5</a> provides the mean weight change from baseline and the proportion of patients with a <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of â‰¥7% categorized by Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index (BMI) at baseline.
</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6: Weight Change Results Categorized by BMI at Baseline: Comparator-Controlled 52-Week Study in Adults with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</span></caption>
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">BMI &lt;23</span><br><span class="Bold">SAPHRIS</span><br><span class="Bold">N=295</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">BMI 23 - â‰¤27</span><br><span class="Bold">SAPHRIS</span><br><span class="Bold">N=290</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">BMI &gt;27</span><br><span class="Bold">SAPHRIS</span><br><span class="Bold">N=302</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Mean change from Baseline (kg)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1.7
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">% with â‰¥7% increase in body weight
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>22%
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>13%
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>9%
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-5.5.6"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Italics">Pediatric Patients:</span> Data on mean changes in body weight and the proportion of pediatric patients meeting a <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> criterion of â‰¥7% of body weight from the short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trial are presented in <span class="Bold"><a href="#t7">Table 7</a></span>. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of pediatric patients by comparisons to age- and sex-matched population standards.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The distance of a z-score from 0 represents the distance of a percentile from the median, measured in standard deviations (SD). After adjusting for age and sex, the mean change from baseline to endpoint in weight z-score for SAPHRS 2.5 mg, 5 mg, and 10 mg twice daily, was 0.11, 0.08 and 0.09 SD versus 0.02 SD for placebo, respectively.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>When treating pediatric patients, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> should be monitored and assessed against that expected for normal growth.
</p>
<a name="t7"></a><table width="100%">
<caption><span>Table 7: Change in Body Weight in Pediatric Subjects from Baseline
</span></caption>
<col align="left" width="16.140%">
<col align="left" width="19.060%">
<col align="left" width="21.920%">
<col align="left" width="20.960%">
<col align="left" width="21.920%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">N* = Number of subjects who had assessments at both Baseline and Endpoint.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (3-weeks)
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">
<br><br>Placebo<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">SAPHRIS<br>2.5 mg<br>twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">SAPHRIS<br>5 mg<br>twice daily
</td>
<td class="Botrule Rrule" align="center" valign="top">SAPHRIS<br>10 mg<br>twice daily
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Change from Baseline (kg) (N*)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.5<br>(89)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.7<br>(92)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.6<br>(90)
</td>
<td class="Botrule Rrule" align="center" valign="top">1.4<br>(87)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top">Proportion of Subjects with a â‰¥7% Increase in Body Weight
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">% with â‰¥7% increase in body weight
</td>
<td class="Botrule Rrule" align="center" valign="top">1.1%
</td>
<td class="Botrule Rrule" align="center" valign="top">12.0%
</td>
<td class="Botrule Rrule" align="center" valign="top">8.9%
</td>
<td class="Botrule Rrule" align="center" valign="top">8.0%
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-5.6"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have been observed in patients treated with SAPHRIS. In several cases, these reactions occurred after the first dose. These <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> included: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">swollen tongue</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-5.7"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.7 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, and Other Hemodynamic Effects
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>SAPHRIS may induce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> in some patients, especially early in treatment, because of its Î±<span class="Sub">1</span>-adrenergic antagonist activity. In short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> adult trials, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported in 0.2% (1/572) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of SAPHRIS, compared to 0.3% (1/378) of patients treated with placebo. In short-term bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> adult trials, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported in 0.3% (1/379) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of SAPHRIS, compared to 0% (0/203) of patients treated with placebo. During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported in 0.6% (11/1953) of patients treated with SAPHRIS. In a 3-week, bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> pediatric trial, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported in 1% (1/104) of patients treated with SAPHRIS 2.5 mg twice daily, 1% (1/99) of patients treated with SAPHRIS 5 mg twice daily, and 0% (0/99) for patients treated with SAPHRIS 10 mg twice daily compared to 0% (0/101) for patients treated with placebo.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Patients should be instructed about non-pharmacologic interventions that help to reduce the occurrence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (e.g., sitting on the edge of the bed for several minutes before attempting to stand in the morning and slowly rising from a seated position). SAPHRIS should be used with caution in (1) patients with known cardiovascular disease (history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, and treatment with antihypertensive medications); and (2) in the elderly. SAPHRIS should be used cautiously when treating patients who receive treatment with other drugs that can induce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, respiratory or central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> <span class="Italics">[see Drug Interactions (<a href="#s64">7.1</a>)]</span>. Monitoring of orthostatic vital signs should be considered in all such patients, and a dose reduction should be considered if <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-5.8"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.8 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>In clinical trial and postmarketing experience, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have been reported temporally related to antipsychotic agents, including SAPHRIS. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> (including fatal cases) has been reported with other agents in the class.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) and history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. In patients with a pre-existing low WBC/ANC or drug-induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of SAPHRIS at the first sign of a clinically significant decline in WBC in the absence of other causative factors.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Monitor patients with clinically significant <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treat promptly if such symptoms or signs occur. Discontinue SAPHRIS in patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt;1000/mm<span class="Sup">3</span>) and follow their WBC until recovery.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-5.9"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.9 QT Prolongation
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>The effects of SAPHRIS on the QT/QTc interval were evaluated in a dedicated adult QT study. This trial involved SAPHRIS doses of 5 mg, 10 mg, 15 mg, and 20 mg twice daily, and placebo, and was conducted in 151 clinically stable patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, with electrocardiographic assessments throughout the dosing interval at baseline and steady state. At these doses, SAPHRIS was associated with increases in QTc interval ranging from 2 to 5 msec compared to placebo. No patients treated with SAPHRIS experienced QTc increases â‰¥60 msec from baseline measurements, nor did any patient experience a QTc of â‰¥500 msec.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Electrocardiogram (ECG) measurements were taken at various time points during the SAPHRIS clinical trial program (5 mg or 10 mg twice daily doses). Post-baseline QT prolongations exceeding 500 msec were reported at comparable rates for SAPHRIS and placebo in these short-term trials. There were no reports of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> or any other adverse reactions associated with delayed ventricular repolarization.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The use of SAPHRIS should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). SAPHRIS should also be avoided in patients with a history of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and in other circumstances that may increase the risk of the occurrence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in association with the use of drugs that prolong the QTc interval, including <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>; and presence of congenital prolongation of the QT interval.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-5.10"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.10 <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Like other drugs that antagonize dopamine D<span class="Sub">2</span> receptors, SAPHRIS can elevate prolactin levels, and the elevation can persist during chronic administration. <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported in patients receiving prolactin-elevating compounds. Long-standing <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> when associated with <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> may lead to decreased bone density in both female and male subjects. In SAPHRIS adult clinical trials, the incidences of adverse events related to abnormal prolactin levels were 0.4% versus 0% for placebo. In a 3-week, bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> pediatric trial, the incidence of adverse events related to abnormal prolactin levels were 0% in the SAPHRIS 2.5 mg twice daily treatment group, 2% in the SAPHRIS 5 mg twice daily treatment group, and 1% in the SAPHRIS 10 mg twice daily treatment group versus to 1% for patients treated with placebo <span class="Italics">[see Adverse Reactions (<a href="#s39">6.1</a>)]</span>.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent <span class="Italics">in vitro</span>, a factor of potential importance if the prescription of these drugs is considered in a patient with previously-detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-5.11"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.11 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> were reported in 0% and 0.3% (0/572, 1/379) of  adult patients treated with doses of 5 mg and 10 mg twice daily of SAPHRIS, respectively, compared to 0% (0/503, 0/203) of patients treated with placebo in short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, respectively. During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were reported in 0.3% (5/1953) of patients treated with SAPHRIS. There were no reports of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in pediatric patients treated with SAPHRIS in a 3-week-term, bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trial.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>As with other antipsychotic drugs, SAPHRIS should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. Conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold may be more prevalent in patients 65 years or older.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-5.12"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.12 Potential for Cognitive and Motor Impairment
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> was reported in patients treated with SAPHRIS. It was usually transient with the highest incidence reported during the first week of treatment. In short-term, fixed-dose, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> adult trials, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported in 15% (41/274) of patients on SAPHRIS 5 mg twice daily and in 13% (26/208) of patients on SAPHRIS 10 mg twice daily compared to 7% (26/378) of placebo patients. In short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> adult trials of therapeutic doses (5-10 mg twice daily), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported in 24% (90/379) of patients on SAPHRIS compared to 6% (13/203) of placebo patients. During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported in 18% (358/1953) of patients treated with SAPHRIS. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> (including sedation) led to discontinuation in 0.6% (12/1953) of patients in short-term, placebo-controlled trials.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>In a 3-week, placebo-controlled, bipolar I pediatric trial, the incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (including sedation and <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>) for placebo, SAPHRIS 2.5 mg twice daily, 5 mg twice daily, and 10 mg twice daily, was  12% (12/101), 46% (48/104), 53% (52/99), and 49% (49/99), respectively.  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> led to discontinuation in 0%, 3%, 1%, and 2% of patients treated with placebo, and SAPHRIS 2.5 mg twice daily, 5 mg twice daily, and 10 mg twice daily, respectively.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that SAPHRIS therapy does not affect them adversely.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-5.13"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.13 Body Temperature Regulation
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. In the short-term placebo-controlled trials for both <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and acute bipolar disorder, the incidence of adverse reactions suggestive of body temperature increases was low (â‰¤1%) and comparable to placebo (0%). During clinical trials with SAPHRIS, including long-term trials without comparison to placebo, the incidence of adverse reactions suggestive of body temperature increases (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> and <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling hot</span>) was â‰¤1%.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>Appropriate care is advised when prescribing SAPHRIS for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-5.14"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.14 <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> illnesses and bipolar disorder, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for SAPHRIS should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-5.15"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.15 <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>
</h2>
<p class="First">Esophageal dysmotility and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> have been associated with antipsychotic drug use. <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> was reported in 0.2% and 0% (1/572, 0/379) of patients treated with therapeutic doses (5-10 mg twice daily) of SAPHRIS as compared to 0% (0/378, 0/203) of patients treated with placebo in short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> adult trials, respectively. During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> was reported in 0.1% (2/1953) of patients treated with SAPHRIS.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span><span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonia</span> is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. SAPHRIS is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, and should not be used in patients at risk for <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span> <span class="Italics">[see also Warnings and Precautions (<a href="#s16">5.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-5.16"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>5.16 Use in Patients with Concomitant Illness
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Clinical experience with SAPHRIS in patients with certain concomitant systemic illnesses is limited <span class="Italics">[see Clinical Pharmacology (<a href="#s94">12.3</a>)]</span>.
</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>SAPHRIS has not been evaluated in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease. Patients with these diagnoses were excluded from pre-marketing clinical trials. Because of the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> with SAPHRIS, caution should be observed in cardiac patients <span class="Italics">[see Warnings and Precautions (<a href="#s28">5.7</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s38"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:
</p>
<ul class="Disc">
<li>Use in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> <span class="Italics">[see <a href="#s3">Boxed Warning</a> and Warnings and Precautions (<a href="#s16">5.1</a> and <a href="#s17">5.2</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> <span class="Italics">[see Warnings and Precautions (<a href="#s18">5.3</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> <span class="Italics">[see Warnings and Precautions (<a href="#s19">5.4</a>)]</span>
</li>
<li>Metabolic Changes <span class="Italics">[see Warnings and Precautions (<a href="#s20">5.5</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> <span class="Italics">[see Contraindications, Warnings and Precautions (<a href="#s27">5.6</a>) and Patient Counseling Information (<a href="#s114">17</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reactions</span> including oral <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>/<span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> <span class="Italics">[see Adverse Reactions (<a href="#s62">6.2</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, and other Hemodynamic Effects <span class="Italics">[see Warnings and Precautions (<a href="#s28">5.7</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> <span class="Italics">[see Warnings and Precautions (<a href="#s29">5.8</a>)]</span>
</li>
<li>QT Interval Prolongation <span class="Italics">[see Warnings and Precautions (<a href="#s30">5.9</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> <span class="Italics">[see Warnings and Precautions (<a href="#s31">5.10</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <span class="Italics">[see Warnings and Precautions (<a href="#s32">5.11</a>)]</span>
</li>
<li>Potential for Cognitive and Motor Impairment <span class="Italics">[see Warnings and Precautions (<a href="#s33">5.12</a>)]</span>
</li>
<li>Body Temperature Regulation <span class="Italics">[see Warnings and Precautions (<a href="#s34">5.13</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> <span class="Italics">[see Warnings and Precautions (<a href="#s35">5.14</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> <span class="Italics">[see Warnings and Precautions (<a href="#s36">5.15</a>)]</span>
</li>
<li>Use in Patients with Concomitant Illness <span class="Italics">[see Warnings and Precautions (<a href="#s37">5.16</a>)]</span>
</li>
</ul>
<p>The most common adverse reactions (â‰¥5% and at least twice the rate of placebo) reported with acute treatment in adults with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> were <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. The safety profile of SAPHRIS in the maintenance treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in adults was similar to that seen with acute treatment.
</p>
<p>The most common adverse reactions (â‰¥5% and at least twice the rate of placebo) reported with acute monotherapy treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> in adults were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> other than <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, and increased weight and during the adjunctive therapy trial in <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> in adults were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>.
</p>
<p>The adult information below is derived from a clinical trial database for SAPHRIS consisting of over 4565 patients and/or healthy subjects exposed to one or more sublingual doses of SAPHRIS. A total of 1314 SAPHRIS-treated patients were treated for at least 24 weeks and 785 SAPHRIS-treated patients had at least 52 weeks of exposure at therapeutic doses.
</p>
<p>In a 3-week monotherapy trial, the most common adverse reactions (â‰¥5% and at least twice the rate of placebo) reported in pediatric patients with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> treated with SAPHRIS were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and increased weight. No new major safety findings were reported from a 50-week, open-label, uncontrolled safety trial.
</p>
<p>A total of 651 pediatric patients were treated with SAPHRIS.  Of these patients, 352 pediatric patients were treated with SAPHRIS for at least 180 days and 58 pediatric patients treated with SAPHRIS had at least 1 year of exposure. The safety of SAPHRIS was evaluated in 403 pediatric patients with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> who participated in a  3-week, placebo-controlled, double-blind trial, of whom 302 patients received SAPHRIS at fixed doses ranging from 2.5 mg to 10 mg twice daily.
</p>
<p> The stated frequencies of adverse reactions represent the proportion of individuals who experienced a treatment-emergent adverse event of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Adult Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>:</span> The following findings are based on the short-term placebo-controlled pre-marketing trials for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (a pool of three 6-week fixed-dose trials and one 6-week flexible-dose trial) in which sublingual SAPHRIS was administered in doses ranging from 5 to 10 mg twice daily.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics Underline">Adverse Reactions Associated with Discontinuation of Treatment:</span> A total of 9% of SAPHRIS-treated patients and 10% of placebo-treated patients discontinued due to adverse reactions. There were no drug-related adverse reactions associated with discontinuation in patients treated with SAPHRIS at the rate of at least 1% and at least twice the placebo rate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Italics Underline">Adverse Reactions Occurring at an Incidence of 2% or More in SAPHRIS-Treated  Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>:</span> Adverse reactions associated with the use of SAPHRIS (incidence of 2% or greater, rounded to the nearest percent, and SAPHRIS incidence greater than placebo) that occurred during acute therapy (up to 6-weeks in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>) are shown in <span class="Bold"><a href="#t8">Table 8</a></span>.
</p>
<a name="t8"></a><table width="100%">
<caption><span>Table 8: Adverse Reactions Reported in 2% or More of Adult Patients in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in 6-Week <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> Trials
</span></caption>
<col align="left" width="38.020%">
<col align="left" width="14.340%">
<col align="left" width="13.660%">
<col align="left" width="15.160%">
<col align="left" width="18.820%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote">* <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> includes: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> and <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>.
</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">â€ </span> <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> included <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyration</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span> (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>).
</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">â€¡</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> includes the following events: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, sedation, and <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>.
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">Â§</span> Also includes the Flexible-dose trial (N=90).
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">System Organ Class/ Preferred Term</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<br><span class="Bold">Placebo</span><br><span class="Bold">N=378</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">SAPHRIS 5 mg twice daily</span><br><span class="Bold">N=274</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">SAPHRIS 10 mg twice daily</span><br><span class="Bold">N=208</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">All SAPHRIS</span><span class="Sup">Â§</span><br><span class="Bold">5 mg or</span><br><span class="Bold">10 mg twice daily</span><br><span class="Bold">N=572</span><br><span class="Bold">%</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach discomfort</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">General disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Investigations</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Increased weight
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>*
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">11
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>)<span class="Sup">â€ </span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><span class="Sup">â€¡</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Psychiatric disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
<td class="Botrule Rrule" align="center" valign="top">16
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
<td class="Botrule Rrule" align="center" valign="top">15
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Italics Underline">Dose-Related Adverse Reactions:</span> In the short term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> appeared to be dose-related (see <a href="#t8">Table 8</a>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold Italics">Monotherapy in Adult Patients with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>:</span> The following findings are based on the short-term placebo-controlled trials for bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (a pool of two 3-week flexible-dose trials) in which sublingual SAPHRIS was administered in doses of 5 mg or 10 mg twice daily.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Italics Underline">Adverse Reactions Associated with Discontinuation of Treatment:</span> Approximately 10% (38/379) of SAPHRIS-treated patients in short-term, placebo-controlled trials discontinued treatment due to an adverse reaction, compared with about 6% (12/203) on placebo. The most common adverse reactions associated with discontinuation in patients treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (1.1%) and oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span> (1.1%) compared to placebo (0%).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-6.1.7"></a><p></p>
<p class="First"><span class="Italics Underline">Adverse Reactions Occurring at an Incidence of 2% or More Among SAPHRIS-Treated (Monotherapy) patients with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>:</span> Adverse reactions associated with the use of SAPHRIS (incidence of 2% or greater, rounded to the nearest percent, and SAPHRIS incidence greater than placebo) that occurred during acute monotherapy (up to 3-weeks in patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>) are shown in <span class="Bold"><a href="#t9">Table 9</a></span>.
</p>
<a name="t9"></a><table width="100%">
<caption><span>Table 9: Adverse Reactions Reported in 2% or More of Adult Patients in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in 3-Week Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Trials
</span></caption>
<col align="left" width="47.749%">
<col align="left" width="21.507%">
<col align="left" width="30.744%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">* SAPHRIS 5 mg to 10 mg twice daily with flexible dosing.
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">â€ </span> <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> included: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="435802" conceptname="Blepharospasm">blepharospasm</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="4013001" conceptname="Masklike facies">masked facies</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>).
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">â€¡</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> includes the following events: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, sedation, and <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">System Organ Class/Preferred Term</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Placebo</span><br><span class="Bold">N=203</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">SAPHRIS</span><br><span class="Bold">5 mg or 10 mg twice daily*</span><br><span class="Bold">N=379</span><br><span class="Bold">%</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">Toothache</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">General disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Investigations</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Increased weight
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Metabolism disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">11
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">11
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Other <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>)<span class="Sup">â€ </span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><span class="Sup">â€¡</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">24
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Psychiatric disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-6.1.8"></a><p></p>
<p class="First"><span class="Bold Italics">Monotherapy in Pediatric Patients with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>:</span> The following findings are based on a 3-week , placebo-controlled trial for bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in which SAPHRIS was administered at doses of 2.5 mg, 5 mg, or 10 mg twice daily.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-6.1.9"></a><p></p>
<p class="First"><span class="Italics Underline">Adverse Reactions Leading to Discontinuation of Treatment:</span> A total of 6.7% (7/104) of patients treated with SAPHRIS 2.5 mg twice daily, 5.1% (5/99) of patients treated with SAPHRIS 5 mg twice daily, and 5.1% (5/99) of patients treated with SAPHRIS 10 mg twice daily discontinued treatment due to adverse reactions compared to 4% (4/101) on placebo. The most common adverse reactions that led to discontinuation in pediatric patients treated with SAPHRIS (rates at least 2% in any SAPHRIS arm and at least twice the placebo rate) were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (3% in the 2.5mg twice daily group, 1% in the 5mg twice daily group, and 2% in the 10mg twice daily group), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2% in the 10mg twice daily group), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2% in the 10mg twice daily group)  No placebo-treated patients dropped out for these events.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-6.1.10"></a><p></p>
<p class="First"><span class="Italics Underline">Adverse Reactions Occurring with SAPHRIS at an Incidence of 2% or More in SAPHRIS-treated Bipolar Patients:</span> Adverse reactions associated with the use of SAPHRIS (incidence of â‰¥2% in any SAPHRIS dose group and greater than placebo) that occurred during acute therapy are shown in <span class="Bold"><a href="#t10">Table 10</a></span>.
</p>
<a name="t10"></a><table width="100%">
<caption><span>Table 10:  Adverse Reactions Reported in 2% or More of Pediatric Patients (Ages 10 to 17 Years) in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in a 3-Week Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Trial
</span></caption>
<col align="left" width="34.350%">
<col align="left" width="9.900%">
<col align="left" width="12.117%">
<col align="left" width="12.117%">
<col align="left" width="11.217%">
<col align="left" width="20.300%">
<tfoot>
<tr class="First"><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">1</span>Includes the preferred terms <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span>.
</p></td></tr>
<tr><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">2</span>Includes the preferred terms oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and oral <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>.
</p></td></tr>
<tr><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">3</span>Includes the preferred terms <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">abdominal pain lower</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>.
</p></td></tr>
<tr><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">4</span>Includes the preferred terms <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>.
</p></td></tr>
<tr><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">5</span>Includes the preferred terms <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinemia</span> and blood insulin increased.
</p></td></tr>
<tr class="Last"><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">6</span>Includes the preferred terms <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, sedation, and <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<span class="Bold">System Organ Class/</span><br><span class="Bold">AE Preferred Term</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br><br><br><span class="Bold">N=101</span><br><span class="Bold">Placebo</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">SAPHRIS</span><br><span class="Bold">2.5 mg</span><br><span class="Bold">twice daily</span><br><span class="Bold">N=104</span><br><span class="Bold">2.5mg</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">SAPHRIS</span><br><span class="Bold">5 mg</span><br><span class="Bold">twice daily</span><br><span class="Bold">N=99</span><br><span class="Bold">5mg</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">SAPHRIS</span><br><span class="Bold">10 mg</span><br><span class="Bold">twice daily</span><br><span class="Bold">N=99</span><br><span class="Bold">10mg</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">All SAPHRIS</span><br><span class="Bold">2.5, 5, and 10 mg</span><br>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">N=101</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">N=104</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">N=99</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">N=99</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">N=302</span><br><span class="Bold">%</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span><span class="Sup">1</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â Oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span><span class="Sup">2</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">25
</td>
<td class="Botrule Rrule" align="center" valign="top">25
</td>
<td class="Botrule Rrule" align="center" valign="top">30
</td>
<td class="Botrule Rrule" align="center" valign="top">27
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><span class="Sup">3</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="441334" conceptname="Glossodynia">Glossodynia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">General Disorders and Administrative Site Disorders</span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><span class="Sup">4</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">14
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications</span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Muscle strain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Investigations</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â Increased weight
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">Hyperinsulinemia</span><span class="Sup">5</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â ALT increased
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â AST increased
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism and Nutrition Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><span class="Sup">6</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">12
</td>
<td class="Botrule Rrule" align="center" valign="top">46
</td>
<td class="Botrule Rrule" align="center" valign="top">53
</td>
<td class="Botrule Rrule" align="center" valign="top">49
</td>
<td class="Botrule Rrule" align="center" valign="top">49
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">11
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">9
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal ideation</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">Anger</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-6.1.11"></a><p></p>
<p class="First"><span class="Italics Underline">Dose-Related Adverse Reactions:</span> In the short term pediatric bipolar trials the incidence of <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> appeared to be dose-related (see <span class="Bold"><a href="#t10">Table 10</a></span>)
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-6.1.12"></a><p></p>
<p class="First"><span class="Bold Italics">Adjunctive Therapy in Adult Patients with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>:</span> The following findings are based on a 12 week placebo-controlled trial (with a 3 week efficacy endpoint) in adult patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in which sublingual SAPHRIS was administered in doses of 5 mg or 10 mg twice daily as adjunctive therapy with lithium or valproate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-6.1.13"></a><p></p>
<p class="First"><span class="Italics Underline">Adverse Reactions Associated with Discontinuation of Treatment:</span> Approximately 16% (25/158) of SAPHRIS-treated patients discontinued treatment due to an adverse reaction, compared with about 11% (18/166) on placebo. The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (2.5%), <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> (2.5%), <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (1.9%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (1.9%) and <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> (1.3%).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-6.1.14"></a><p></p>
<p class="First"><span class="Italics Underline">Adverse Reactions Occurring at an Incidence of 2% or More Among SAPHRIS-Treated (Adjunctive) Bipolar Patients:</span> Adverse reactions associated with the use of SAPHRIS (incidence of 2% or greater, rounded to the nearest percent, and SAPHRIS incidence greater than placebo) that occurred during acute adjunctive therapy at 3 weeks, a time when most of the patients were still participating in the trial, are shown in <span class="Bold"><a href="#t11">Table 11</a></span>.
</p>
<a name="t11"></a><table width="100%">
<caption><span>Table 11: Adverse Reactions Reported in 2% or More of Adult Patients In Any SAPHRIS-Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group at 3 Weeks in Adjunctive Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Trials
</span></caption>
<col align="left" width="47.500%">
<col align="left" width="20.400%">
<col align="left" width="32.100%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">* SAPHRIS 5 mg to 10 mg twice daily with flexible dosing.
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">â€ </span> <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> included: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyration</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>).
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">â€¡</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> includes the following events: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and sedation.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">System Organ Class/Preferred Term</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Placebo</span><br><span class="Bold">N=166</span><br><span class="Bold">%</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">SAPHRIS</span><br><span class="Bold">5 mg or 10 mg twice daily*</span><br><span class="Bold">N=158</span><br><span class="Bold">%</span>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â Oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">General disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Investigations</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â Increased weight
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â Other <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> (excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>)<span class="Sup">â€ </span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><span class="Sup">â€¡</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
<td class="Botrule Rrule" align="center" valign="top">22
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold">Psychiatric disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
<td class="Botrule Rrule" align="center" valign="top">10
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-6.1.15"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span>:</span> Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups <span class="Italics">[see Dosage and Administration (<a href="#s8">2.3</a>), Use in Specific Populations (<a href="#s76">8.4</a>), and Clinical Pharmacology (<a href="#s94">12.3</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-6.1.16"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span>:</span> In the short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> adult trials, data was objectively collected on the Simpson Angus Rating Scale for <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> (EPS), the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale (for <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>) and the Assessments of Involuntary Movement Scales (for <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span>). The mean change from baseline for the all-SAPHRIS 5 mg or 10 mg twice daily treated group was comparable to placebo in each of the rating scale scores.
</p>
<p>In the short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> adult trials, the incidence of reported EPS-related events, excluding events related to <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, for SAPHRIS-treated patients was 10% versus 7% for placebo; and the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>-related events for SAPHRIS-treated patients was 6% versus 3% for placebo. In short-term placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> adult trials, the incidence of EPS-related events, excluding events related to <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, for SAPHRIS-treated patients was 7% versus 2% for placebo; and the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>-related events for SAPHRIS-treated patients was 4% versus 2% for placebo.
</p>
<p>In a 3-week, placebo-controlled pediatric trial with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>, the incidences of EPS-related events, excluding events related to <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, were 4%, 3%, and 5% for patients treated with SAPHRIS 2.5 mg, 5 mg, and 10 mg twice daily, respectively, as compared to 3% for placebo-treated patients. EPS-related events include: <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, oromandibular <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">muscle contractions involuntary</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, protrusion tongue, resting <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.
</p>
<p>For events of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, incidences were 2%, 2%, and 1% for patients treated with SAPHRIS 2.5 mg, 5 mg, and 10 mg twice daily, respectively, as compared to 0% for placebo-treated patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-6.1.17"></a><p></p>
<p class="First"><span class="Bold Italics">Other Findings:</span> Oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span> and/or oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> may occur directly after administration of SAPHRIS and usually resolves within 1 hour.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-6.1.18"></a><p></p>
<p class="First"><span class="Bold Italics">Laboratory Test Abnormalities:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-6.1.19"></a><p></p>
<p class="First"><span class="Italics Underline">Transaminases:</span> Transient elevations in serum transaminases (primarily ALT) in the short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> adult trials were more common in treated patients. In short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> adult trials, the mean increase in transaminase levels for SAPHRIS-treated patients was 1.6 units/L compared to a decrease of 0.4 units/L for placebo-treated patients. The proportion of patients with transaminase elevations â‰¥3 times ULN (at Endpoint) was 0.9% for SAPHRIS-treated patients versus 1.3% for placebo-treated patients. In short-term, placebo-controlled bipolar adult <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trials, the mean increase in transaminase levels for SAPHRIS-treated patients was 8.9 units/L compared to a decrease of 4.9 units/L in placebo-treated patients. The proportion of patients with transaminase elevations â‰¥3 times upper limit of normal (ULN) (at Endpoint) was 2.5% for SAPHRIS-treated patients versus 0.6% for placebo-treated patients.
</p>
<p>In a 52-week, double-blind, comparator-controlled trial that included primarily adult patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean increase from baseline of ALT was 1.7 units/L.
</p>
<p>In a 3-week, placebo-controlled pediatric trial with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>, transient elevations in serum transaminases (primarily ALT) were more common in treated patients. The proportion of pediatric patients with ALT elevations â‰¥3 times upper limit of normal (ULN) was 2.4% for patients treated with SAPHRIS 10 mg twice daily versus none for the other SAPHRIS dose groups and placebo-treated patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-6.1.20"></a><p></p>
<p class="First"><span class="Italics Underline">Prolactin:</span> In short-term, placebo-controlled adult <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, the mean decreases in prolactin levels were 6.5 ng/mL for SAPHRIS-treated patients compared to 10.7 ng/mL for placebo-treated patients. The proportion of patients with prolactin elevations â‰¥4 times ULN (at Endpoint) were 2.6% for SAPHRIS-treated patients versus 0.6% for placebo-treated patients. In short-term, placebo-controlled bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> adult trials, the mean increase in prolactin levels was 4.9 ng/mL for SAPHRIS-treated patients compared to a decrease of 0.2 ng/mL for placebo-treated patients. The proportion of patients with prolactin elevations â‰¥4 times ULN (at Endpoint) were 2.3% for SAPHRIS-treated patients versus 0.7% for placebo-treated patients.
</p>
<p>In a long-term (52-week), double-blind, comparator-controlled adult trial that included primarily patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean decrease in prolactin from baseline for SAPHRIS-treated patients was 26.9 ng/mL.
</p>
<p>In a 3-week, placebo-controlled pediatric trial with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>, the mean increases (at Endpoint) in prolactin levels were 3.2 ng/mL for patients treated with SAPHRIS 2.5 mg twice daily, 2.1 ng/mL for patients treated with SAPHRIS 5 mg twice daily, and 6.4 ng/mL for patients treated with SAPHRIS 10 mg twice daily compared to an increase of 2.5 ng/mL for placebo-treated patients. There were no reports of prolactin elevations â‰¥4 times ULN (at Endpoint) for patients treated with SAPHRIS or placebo. <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span> or <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> were reported in 0% of patients treated with SAPHRIS 2.5 mg twice daily, 2% of patients treated with SAPHRIS 5 mg twice daily, and 1% of patients treated with SAPHRIS 10 mg twice daily compared to 1% of placebo-treated patients.  There were no reports of <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> in this trial.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-6.1.21"></a><p></p>
<p class="First"><span class="Italics Underline">Creatine Kinase (CK):</span> The proportion of adult patients with CK elevations &gt;3 times ULN at any time were 6.4% and 11.1% for patients treated with SAPHRIS 5 mg twice daily and 10 mg twice daily, respectively, as compared to 6.7% for placebo-treated patients in short-term, fixed-dose trials in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>. The clinical relevance of this finding is unknown.
</p>
<p>The proportion of patients with CK elevations â‰¥3 times ULN during a 3-week trial in pediatric <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> at any time were 1%, 0%, and 1% for patients treated with SAPHRIS 2.5 mg, 5 mg, and 10 mg twice daily, respectively, versus 3% for placebo-treated patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-6.1.22"></a><p></p>
<p class="First"><span class="Bold Italics">Other Adverse Reactions Observed During the Premarketing Evaluation of SAPHRIS:</span> Following is a list of MedDRA terms that reflect adverse reactions reported by patients treated with sublingual SAPHRIS at multiple doses of â‰¥5 mg twice daily during any phase of a trial within the database of adult patients. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions already listed for either adults or pediatric patients in other parts of <span class="Italics">Adverse Reactions (<a href="#s38">6</a>)</span>, or those considered in <span class="Italics">Contraindications (<a href="#s14">4</a>), Warnings and Precautions (<a href="#s15">5</a>)</span> or <span class="Italics">Overdosage (<a href="#s87">10</a>)</span> are not included. Reactions are further categorized by MedDRA system organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (frequent) (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); those occurring in 1/100 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 patients (rare).
</p>
<dl>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline">Blood and lymphatic disorders:
</span><span class="Italics"> infrequent:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>; <span class="Italics">rare:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:
</span><span class="Italics">infrequent:</span> temporary <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:
</span><span class="Italics">infrequent:</span> <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">accommodation disorder</span>
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:
</span><span class="Italics">infrequent:</span> <span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">swollen tongue</span>
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline">General disorders:
</span><span class="Italics">rare:</span> idiosyncratic drug reaction
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline">Investigations:
</span><span class="Italics">infrequent:</span> <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:
</span><span class="Italics">infrequent:</span> <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>
</dd>
</dl>
<p>Following is a list of MedDRA terms not already listed either for adults or pediatric patients in other parts of <span class="Italics">Adverse Reactions (<a href="#s38">6</a>)</span>, or those considered in <span class="Italics">Contraindications (<a href="#s14">4</a>), Warnings and Precautions (<a href="#s15">5</a>)</span> or <span class="Italics">Overdosage (<a href="#s87">10</a>)</span> that reflect adverse reactions reported by pediatric patients (Ages 10 to 17 years) treated with sublingual SAPHRIS at doses of 2.5 mg, 5 mg, or 10 mg twice daily during any phase of a trial within the database of pediatric patients.
</p>
<dl>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:
</span><span class="Italics">infrequent:</span> <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:
</span><span class="Italics">infrequent:</span> <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications:
</span><span class="Italics">infrequent</span>: <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline">Skin and subcutaneous tissue disorders:
</span><span class="Italics">infrequent:</span> <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>
</dd>
<dt>Â 
</dt>
<dd>
<span class="Italics Underline">Renal and urinary disorders: infrequent:
</span><span class="Underline"><span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span></span>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of SAPHRIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to establish a causal relationship to drug exposure.  In many cases, the occurrence of these adverse reactions led to discontinuation of therapy.
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reactions</span>, primarily in the sublingual area, have been reported. These <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> included oral <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>/<span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span>, and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.
</li>
<li><span class="product-label-link" type="condition" conceptid="4096712" conceptname="Choking">Choking</span> has been reported by patients, some of whom may have also experienced oropharyngeal muscular dysfunction or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>.
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s63"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs Having Clinically Important Drug Interactions with SAPHRIS
</h2>
<a name="t12"></a><table width="100%">
<caption><span>Table 12: Clinically Important Drug Interactions with SAPHRIS
</span></caption>
<col align="left" width="25.500%">
<col align="left" width="44.933%">
<col align="left" width="29.567%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Concomitant Drug Name or Drug Class</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Clinical Rationale</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Clinical Recommendation</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="justify" valign="top">Antihypertensive Drugs<br>
</td>
<td class="Botrule Rrule" align="justify" valign="top">Because of its Î±<span class="Sub">1</span>-adrenergic antagonism with potential for inducing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, SAPHRIS may enhance the effects of certain antihypertensive agents <span class="Italics">[see Warnings and Precautions (<a href="#s28">5.7</a>)]</span>.
</td>
<td class="Botrule Rrule" align="justify" valign="top">Monitor blood pressure and adjust dosage of antihypertensive drug accordingly.
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="justify" valign="top">Strong CYP1A2 Inhibitors (e.g., Fluvoxamine)
</td>
<td class="Botrule Rrule" align="justify" valign="top">SAPHRIS is metabolized by CYP1A2. Marginal increase of asenapine exposure was observed when SAPHRIS is used with fluvoxamine at 25 mg administered twice daily <span class="Italics">[see Clinical Pharmacology (<a href="#s94">12.3</a>)]</span>. However, the tested fluvoxamine dose was suboptimal. Full therapeutic dose of fluvoxamine is expected to cause a greater increase in asenapine exposure.
</td>
<td class="Botrule Rrule" align="justify" valign="top">Dosage reduction for SAPHRIS based on clinical response may be necessary.
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="justify" valign="top">CYP2D6 substrates and inhibitors (e.g., paroxetine)
</td>
<td class="Botrule Rrule" align="justify" valign="top">SAPHRIS may enhance the inhibitory effects of paroxetine on its own metabolism. Concomitant use of paroxetine with SAPHRIS increased the paroxetine exposure by 2-fold as compared to use paroxetine alone <span class="Italics">[see Clinical Pharmacology (<a href="#s94">12.3</a>)].</span>
</td>
<td class="Botrule Rrule" align="justify" valign="top">Reduce paroxetine dose by half when paroxetine is used in combination with SAPHRIS.
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs Having No Clinically Important Interactions with SAPHRIS
</h2>
<p class="First">No dosage adjustment of SAPHRIS is necessary when administered concomitantly with paroxetine (see <a href="#t9">Table 9</a> in Drug Interactions (<a href="#s64">7.1</a>) for paroxetine dosage adjustment), imipramine, cimetidine, valporate, lithium, or a CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin).
</p>
<p>In addition, valproic acid and lithium pre-dose serum concentrations collected from an adjunctive therapy study were comparable between asenapine-treated patients and placebo-treated patients indicating a lack of effect of asenapine on valproic and lithium plasma levels.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s66"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s67"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Exposure Registry</span></p>
<p>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to SAPHRIS during pregnancy. For more information contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit <span class="Underline">http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Bold">Risk Summary</span></p>
<p>Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. Studies have not been conducted with SAPHRIS in pregnant women.  There are no available human data informing the drug-associated risk. The background risk of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> for the indicated populations are unknown. However, the background risk in the U.S. general population of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> is 2-4% and of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> is 15-20% of clinically recognized pregnancies.  No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed in animal reproduction studies with intravenous administration of asenapine to rats and rabbits during organogenesis at doses 0.7 and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 10 mg sublingually twice daily. In a pre-and post-natal study in rats, intravenous administration of asenapine at doses up to 0.7 times the MRHD produced increases in post-implantation loss and early pup <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, and decreases in subsequent pup survival and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> <span class="Italics">[see Data].</span> Advise pregnant women of the potential risk to a fetus.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-8.1.3"></a><p></p>
<p class="First"><span class="Bold">Clinical Considerations</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-8.1.4"></a><p></p>
<p class="First"><span class="Underline">Fetal/Neonatal Adverse Reactions</span></p>
<p>Extrapyramidal and/or withdrawal symptoms, including <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> have been reported in neonates who were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-8.1.5"></a><p></p>
<p class="First"><span class="Bold">Data</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-8.1.6"></a><p></p>
<p class="First"><span class="Underline">Animal Data</span></p>
<p>In animal studies, asenapine increased post-implantation loss and decreased pup weight and survival at doses similar to or less than recommended clinical doses. In these studies there was no increase in the incidence of structural abnormalities caused by asenapine.
</p>
<p>Asenapine was not teratogenic in reproduction studies in rats and rabbits at intravenous doses up to 1.5 mg/kg in rats and 0.44 mg/kg in rabbits administered during organogenesis. These doses are 0.7 and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 10 mg twice daily given sublingually on a mg/m<span class="Sup">2</span> basis. Plasma levels of asenapine were measured in the rabbit study, and the area under the curve (AUC) at the highest dose tested was 2 times that in humans receiving the MRHD.
</p>
<p>In a study in which rats were treated from day 6 of gestation through day 21 postpartum with intravenous doses of asenapine of 0.3, 0.9, and 1.5 mg/kg/day (0.15, 0.4, and 0.7 times the MRHD of 10 mg twice daily given sublingually on a mg/m<span class="Sup">2</span> basis), increases in post-implantation loss and early pup <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were seen at all doses, and decreases in subsequent pup survival and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> were seen at the two higher doses. A cross-fostering study indicated that the decreases in pup survival were largely due to prenatal drug effects. Increases in post-implantation loss and decreases in pup weight and survival were also seen when pregnant rats were dosed orally with asenapine.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Lactation
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-8.2.1"></a><p></p>
<p class="First"><span class="Bold">Risk Summary</span></p>
<p> Lactation studies have not been conducted to assess the presence of asenapine in human milk, the effects of asenapine on the breastfed infant, or the effects of asenapine on milk production. Asenapine is excreted in rat milk .The development and health benefits of breastfeeding should be considered along with the mother's clinical need for SAPHRIS and any potential adverse effects on the breastfed infant from SAPHRIS or from the underlying maternal condition.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s76"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and efficacy of SAPHRIS in pediatric patients below the age of 10 years of age have not been evaluated.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-8.3.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span></span></p>
<p>The safety and efficacy of SAPHRIS as monotherapy in the treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> were established in a 3-week, placebo-controlled, double-blind trial of 403 pediatric patients 10 to 17 years of age, of whom 302 patients received SAPHRIS at fixed doses ranging from 2.5 mg to 10 mg twice daily <span class="Italics">[see Dosage and Administration (<a href="#s8">2.3</a>), Adverse Reactions (<a href="#s39">6.1</a>), Clinical Pharmacology (<a href="#s94">12.3</a>), and Clinical Studies (<a href="#s109">14.2</a>)]</span>. In a Phase 1 study, pediatric patients aged 10 to 17 years appeared to be more sensitive to <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span> with initial dosing with asenapine when the recommended dose escalation schedule was not followed. No new major safety findings were reported from a 50-week, open-label, uncontrolled safety trial in pediatric patients with bipolar disorder treated with SAPHRIS monotherapy. The safety and efficacy of SAPHRIS as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> have not been established in the pediatric population. In general, the pharmacokinetics of asenapine in pediatric patients (10 to17 years) and adults are similar <span class="Italics">[see Clinical Pharmacology (<a href="#s94">12.3</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-8.3.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<p>Efficacy of SAPHRIS was not demonstrated in an 8-week, placebo-controlled, double-blind trial, in 306 adolescent patients aged 12 to17 years with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> at doses of 2.5 and 5 mg twice daily. The most common adverse reactions (proportion of patients equal or greater than 5% and at least twice placebo) reported were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and oral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. The proportion of patients with an equal or greater than 7% increase in body weight at endpoint compared to baseline for placebo, SAPHRIS 2.5 mg twice daily, and SAPHRIS 5 mg twice daily was 3%, 10%, and 10%, respectively.
</p>
<p>The clinically relevant adverse reactions identified in the pediatric <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trial were generally similar to those observed in the pediatric bipolar and adult bipolar and <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials. No new major safety findings were reported from a 26-week, open-label, uncontrolled safety trial in pediatric patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> treated with SAPHRIS monotherapy.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s79"></a><a name="section-8.3.3"></a><p></p>
<p class="First"><span class="Bold">Juvenile Animal Data</span></p>
<p>Subcutaneous administration of asenapine to juvenile rats for 56 days from day 14 of age to day 69 of age at 0.4, 1.2, and 3.2 mg/kg/day (0.2, 0.6 and 1.5 times the maximum recommended human dose of 10 mg twice daily given sublingually on a mg/m<span class="Sup">2</span> basis) resulted in significant reduction in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in animals of both sexes at all dose levels from the start of dosing until weaning. Body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> remained reduced in males to the end of treatment, however, recovery was observed once treatment ended. Neurobehavioral assessment indicated increased motor activity in animals at all dose levels following the completion of treatment, with the evidence of recovery in males. There was no recovery after the end of treatment in female activity pattern as late as day 30 following the completion of treatment (last retesting). Therefore, a No Observed Adverse Effect Level (NOAEL) for the juvenile animal toxicity of asenapine could not be determined. There were no treatment-related effects on the startle response, learning/memory, organ weights, microscopic evaluations of the brain and, reproductive performance (except for minimally reduced conception rate and fertility index in males and females administered 1.2 and 3.2 mg/kg/day).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s80"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Clinical studies of SAPHRIS in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> did not include sufficient numbers of patients aged 65 and over to determine whether or not they respond differently than younger patients. Of the approximately 2250 patients in pre-marketing clinical studies of SAPHRIS, 1.1% (25) were 65 years of age or over. Multiple factors that might increase the pharmacodynamic response to SAPHRIS, causing poorer tolerance or orthostasis, could be present in elderly patients, and these patients should be monitored carefully. Based on a pharmacokinetic study in elderly patients, dosage adjustments are not recommended based on age alone <span class="Italics">[see Clinical Pharmacology (<a href="#s94">12.3</a>)]</span>.
</p>
<p>Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with SAPHRIS are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to placebo. SAPHRIS is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see <a href="#s3">Boxed Warning</a>]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s81"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">No dosage adjustment for SAPHRIS is required on the basis of a patient'srenal function (mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, glomerular filtration rate between 15 and 90 mL/minute). The exposure of asenapine was similar among subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and subjects with normal renal function <span class="Italics">[see Clinical Pharmacology (<a href="#s94">12.3</a>)]</span>. The effect of renal function on the excretion of other metabolites and the effect of dialysis on the pharmacokinetics of asenapine has not been studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s82"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">SAPHRIS is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) because asenapine exposure is 7-fold higher in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> than the exposure observed in subjects with normal hepatic function.
</p>
<p>No dosage adjustment for SAPHRIS is required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh A and B) because asenapine exposure is similar to that in subjects with normal hepatic function<span class="Italics">[see Contraindications (<a href="#s14">4</a>) and Clinical Pharmacology (<a href="#s94">12.3</a>)]</span>.<br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s83"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Other Specific Populations
</h2>
<p class="First">No dosage adjustment for SAPHRIS is required on the basis of a patient's sex, race (Caucasian and Japanese), or smoking status <span class="Italics">[see CLINICAL PHARMACOLOGY (<a href="#s94">12.3</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s84"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</h1>
<div class="Section" data-sectionCode="34085-1">
<a name="s85"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance
</h2>
<p class="First">SAPHRIS is not a controlled substance.
</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="s86"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse
</h2>
<p class="First">SAPHRIS has not been systematically studied in animals or humans for its abuse potential or its ability to induce tolerance or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Thus, it is not possible to predict the extent to which a CNS-active drug will be misused, diverted and/or abused once it is marketed. Patients should be evaluated carefully for a history of drug abuse, and such patients should be observed carefully for signs that they are misusing or abusing SAPHRIS (e.g., drug-seeking behavior, increases in dose).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s87"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s88"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Human Experience:</span> In adult pre-marketing clinical studies involving more than 3350 patients and/or healthy subjects, accidental or intentional acute overdosage of SAPHRIS was identified in 3 patients. Among these few reported cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the highest estimated ingestion of SAPHRIS was 400 mg. Reported adverse reactions at the highest dosage included <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s89"></a><a name="section-10.2"></a><p></p>
<p class="First"><span class="Bold">Management of Overdosage:</span> There is no specific antidote to SAPHRIS. The possibility of multiple drug involvement should be considered. An electrocardiogram should be obtained and management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Consult with a Certified Poison Control Center for up-to-date guidance and advice on the management of overdosage (1-800-222-1222.)
</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in the setting of SAPHRIS-induced alpha blockade). In case of severe <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s90"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">SAPHRIS contains asenapine maleate which is a psychotropic agent that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. The chemical designation is (3a<span class="Italics">RS</span>,12b<span class="Italics">RS</span>)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1<span class="Italics">H</span>dibenzo[2,3:6,7]oxepino[4,5-<span class="Italics">c</span>]pyrrole (2<span class="Italics">Z</span>)-2-butenedioate (1:1). Its molecular formula is C<span class="Sub">17</span>H<span class="Sub">16</span>ClNOÂ·C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and its molecular weight is 401.84 (free base: 285.8). The chemical structure is:
</p>
<p><a name="f01"></a><img alt="Chemical Structure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-01.jpg"></p>
<p>Asenapine maleate is a white to off-white powder.
</p>
<p>SAPHRIS, black cherry flavor, is supplied for sublingual administration in tablets containing 2.5 mg, 5 mg or 10 mg asenapine; inactive ingredients include gelatin, mannitol, sucralose, and black cherry flavor.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s91"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s92"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">The mechanism of action of asenapine, in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and bipolar disorder, is unknown. It has been suggested that the efficacy of asenapine in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> could be mediated through a combination of antagonist activity at D<span class="Sub">2</span> and 5-HT<span class="Sub">2A</span> receptors.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s93"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First">Asenapine exhibits high affinity for serotonin 5-HT<span class="Sub">1A</span>, 5-HT<span class="Sub">1B</span>, 5-HT<span class="Sub">2A</span>, 5-HT<span class="Sub">2B</span>, 5-HT<span class="Sub">2C</span>, 5-HT<span class="Sub">5A</span>, 5-HT<span class="Sub">6,</span> and 5-HT<span class="Sub">7</span> receptors (Ki values of 2.5, 2.7, 0.07, 0.18, 0.03, 1.6, 0.25, and 0.11nM, respectively), dopamine D<span class="Sub">2A</span>, D<span class="Sub">2B</span>, D<span class="Sub">3</span>, D<span class="Sub">4</span>, and D<span class="Sub">1</span> receptors (Ki values of 1.3, 1.4, 0.42, 1.1, and 1.4 nM, respectively), Î±<span class="Sub">1A</span>, Î±<span class="Sub">2A</span>, Î±<span class="Sub">2B</span>, and Î±<span class="Sub">2C</span> -adrenergic receptors (Ki values of 1.2, 1.2, 0.33 and 1.2 nM, respectively), and histamine H<span class="Sub">1</span> receptors (Ki value 1.0 nM), and moderate affinity for H<span class="Sub">2</span> receptors (Ki value of 6.2 nM). In <span class="Italics">in vitro</span> assays asenapine acts as an antagonist at these receptors. Asenapine has no appreciable affinity for muscarinic cholinergic receptors (e.g., Ki value of 8128 nM for M<span class="Sub">1</span>).
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s94"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">Following a single 5 mg dose of SAPHRIS, the mean C<span class="Sub">max</span> was approximately 4 ng/mL and was observed at a mean t<span class="Sub">max</span> of 1 hour. Elimination of asenapine is primarily through direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2). Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs. With multiple-dose twice-daily dosing, steady-state is attained within 3 days. Overall, steady-state asenapine pharmacokinetics are similar to single-dose pharmacokinetics.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s95"></a><a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption:</span> Following sublingual administration, asenapine is rapidly absorbed with peak plasma concentrations occurring within 0.5 to 1.5 hours. The absolute bioavailability of sublingual asenapine at 5 mg is 35%. Increasing the dose from 5 mg to 10 mg twice daily (a two-fold increase) results in less than linear (1.7 times) increases in both the extent of exposure and maximum concentration. The absolute bioavailability of asenapine when swallowed is low (&lt;2% with an oral tablet formulation).
</p>
<p>The intake of water several (2 or 5) minutes after asenapine administration resulted in decreased asenapine exposure. Therefore, eating and drinking should be avoided for 10 minutes after administration <span class="Italics">[see Dosage and Administration (<a href="#s6">2.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s96"></a><a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Bold">Distribution:</span> Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 - 25 L/kg), indicating extensive extravascular distribution. Asenapine is highly bound (95%) to plasma proteins, including albumin and Î±<span class="Sub">1</span>-acid glycoprotein.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s97"></a><a name="section-12.3.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism and Elimination:</span> Direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2) are the primary metabolic pathways for asenapine.
</p>
<p>Asenapine is a high clearance drug with a clearance after intravenous administration of 52 L/h. In this circumstance, hepatic clearance is influenced primarily by changes in liver blood flow rather than by changes in the intrinsic clearance, i.e., the metabolizing enzymatic activity. Following an initial more rapid distribution phase, the terminal half-life of asenapine is approximately 24 hours. Steady-state concentrations of asenapine are reached within 3 days of twice daily dosing.
</p>
<p>After administration of a single dose of [<span class="Sup">14</span>C]-labeled asenapine, about 90% of the dose was recovered; approximately 50% was recovered in urine, and 40% recovered in feces. About 50% of the circulating species in plasma have been identified. The predominant species was asenapine N<span class="Sup">+</span>-glucuronide; others included N-desmethylasenapine, N-desmethylasenapine N-carbamoyl glucuronide, and unchanged asenapine in smaller amounts. SAPHRIS activity is primarily due to the parent drug.
</p>
<p><span class="Italics">In vitro</span> studies indicate that asenapine is a substrate for UGT1A4, CYP1A2 and to a lesser extent CYP3A4 and CYP2D6. Asenapine is a weak inhibitor of CYP2D6. Asenapine does not cause induction of CYP1A2 or CYP3A4 activities in cultured human hepatocytes. Coadministration of asenapine with known inhibitors, inducers or substrates of these metabolic pathways has been studied in a number of drug-drug interaction studies <span class="Italics">[see Drug Interactions (<a href="#s64">7.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s98"></a><a name="section-12.3.4"></a><p></p>
<p class="First"><span class="Bold Italics">Food:</span> A crossover study in 26 healthy adult male subjects was performed to evaluate the effect of food on the pharmacokinetics of a single 5 mg dose of asenapine. Consumption of food immediately prior to sublingual administration decreased asenapine exposure by 20%; consumption of food 4 hours after sublingual administration decreased asenapine exposure by about 10%. These effects are probably due to increased hepatic blood flow.
</p>
<p>In clinical trials establishing the efficacy and safety of SAPHRIS, patients were instructed to avoid eating for 10 minutes following sublingual dosing. There were no other restrictions with regard to the timing of meals in these trials <span class="Italics">[see Dosage and Administration (<a href="#s6">2.1</a>) and Patient Counseling Information (<a href="#s114">17</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s99"></a><a name="section-12.3.5"></a><p></p>
<p class="First"><span class="Bold Italics">Water:</span> In clinical trials establishing the efficacy and safety of SAPHRIS, patients were instructed to avoid drinking for 10 minutes following sublingual dosing. The effect of water administration following 10 mg sublingual SAPHRIS dosing was studied at different time points of 2, 5, 10, and 30 minutes in 15 healthy adult male subjects. The exposure of asenapine following administration of water 10 minutes after sublingual dosing was equivalent to that when water was administered 30 minutes after dosing. Reduced exposure to asenapine was observed following water administration at 2 minutes (19% decrease) and 5 minutes (10% decrease) <span class="Italics">[see Dosage and Administration (<a href="#s6">2.1</a>) and Patient Counseling Information (<a href="#s114">17</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s100"></a><a name="section-12.3.6"></a><p></p>
<p class="First"><span class="Bold">Drug Interaction Studies:</span></p>
<p>Effects of other drugs on the exposure of asenapine are summarized in <a href="#fig1">Figure 1</a>.  In addition, a population pharmacokinetic analysis indicated that the concomitant administration of lithium had no effect on the pharmacokinetics of asenapine.<br><br></p>
<p class="MultiMediaCaption"><a name="fig1"></a><span class="Bold">Figure 1: Effect of Other Drugs on Asenapine Pharmacokinetics</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-02.jpg">
</div>
<p>The effects of asenapine on the pharmacokinetics of other co-administered drugs are summarized in <a href="#fig2">Figure 2</a>.
</p>
<p>Coadministration of paroxetine with SAPHRIS caused a two-fold increase in the maximum plasma concentrations and
</p>
<p>systemic exposure of paroxetine. Asenapine enhances the inhibitory effects of paroxetine on its own metabolism by CYP2D6.<br><br></p>
<p class="MultiMediaCaption"><a name="fig2"></a><span class="Bold">Figure 2: Effect of Asenapine on Other Drug Pharmacokinetics</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s101"></a><a name="section-12.3.7"></a><p></p>
<p class="First"><span class="Bold">Studies in Special Populations:</span></p>
<p>Exposures of asenapine in special populations are summarized in <a href="#fig3">Figure 3</a>. Additionally, based on population pharmacokinetic analysis, no effects of sex, race, BMI, and smoking status on asenapine exposure were observed. Exposure in elderly patients is 30-40% higher as compared to adults.<br><br></p>
<p class="MultiMediaCaption"><a name="fig3"></a><span class="Bold">Figure 3: Effect of Intrinsic Factors on Asenapine Pharmacokinetics</span></p>
<div class="Figure">
<a name="f04"></a><img alt="Figure 3
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-04.jpg">
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s102"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s103"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s104"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Carcinogenesis:</span> In a lifetime carcinogenicity study in CD-1 mice asenapine was administered subcutaneously at doses up to those resulting in plasma levels (AUC) estimated to be 5 times those in humans receiving the MRHD of 10 mg twice daily. The incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span> was increased in female mice, with a no-effect dose resulting in plasma levels estimated to be 1.5 times those in humans receiving the MRHD. The mouse <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> used has a high and variable incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span>, and the significance of these results to humans is unknown. There were no increases in other tumor types in female mice. In male mice, there were no increases in any tumor type.
</p>
<p>In a lifetime carcinogenicity study in Sprague-Dawley rats, asenapine did not cause any increases in tumors when administered subcutaneously at doses up to those resulting in plasma levels (AUC) estimated to be 5 times those in humans receiving the MRHD.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s105"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Mutagenesis:</span> No evidence for genotoxic potential of asenapine was found in the <span class="Italics">in vitro</span> bacterial reverse mutation assay, the <span class="Italics">in vitro</span> forward gene mutation assay in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, the <span class="Italics">in vitro</span> chromosomal aberration assays in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, the <span class="Italics">in vitro</span> sister chromatid exchange assay in rabbit <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, or the <span class="Italics">in vivo</span> micronucleus assay in rats.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s106"></a><a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Bold Italics">Impairment of Fertility:</span> Asenapine did not impair fertility in rats when tested at doses up to 11 mg/kg twice daily given orally. This dose is 10 times the maximum recommended human dose of 10 mg twice daily given sublingually on a mg/m<span class="Sup">2</span> basis.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s107"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">Efficacy of SAPHRIS was established in the following trials:
</p>
<ul class="Disc">
<li>Two fixed-dose, short-term trials and one flexible-dose, maintenance trial in adult patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> as monotherapy [<span class="Italics">see Clinical Studies (<a href="#s108">14.1</a>)]</span>
</li>
<li>Two flexible-dose, short-term trials in adult patients and one fixed-dose, short-term trial in children (10 to 17 years) with <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> as monotherapy [<span class="Italics">see Clinical Studies (<a href="#s109">14.2</a>)</span>]
</li>
<li>One flexible-dose, short-term trial in adult patients with <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> as adjunctive treatment to lithium or valproate [<span class="Italics">see Clinical Studies (<a href="#s109">14.2</a>)</span>]
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s108"></a><a name="section-14.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</h2>
<p class="First">The efficacy of SAPHRIS in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in adults was evaluated in three fixed-dose, short-term (6 week), randomized, double-blind, placebo-controlled, and active-controlled (haloperidol, risperidone, and olanzapine) trials of adult patients who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and were having an acute exacerbation of their schizophrenic illness. In two of the three trials SAPHRIS demonstrated superior efficacy to placebo. In a third trial, SAPHRIS could not be distinguished from placebo; however, an active control in that trial was superior to placebo.
</p>
<p>In the two positive trials for SAPHRIS, the primary efficacy rating scale was the Positive and Negative Syndrome Scale (PANSS). The PANSS is a 30 item scale that measures positive symptoms of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (7 items), negative symptoms of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (7 items), and general psychopathology (16 items), each rated on a scale of 1 (absent) to 7 (extreme); total PANSS scores range from 30 to 210. The primary endpoint was change from baseline to endpoint on the PANSS total score. The results of the SAPHRIS trials in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> follow:
</p>
<p>In trial 1, a 6-week trial (n=174), comparing SAPHRIS (5 mg twice daily) to placebo, SAPHRIS 5 mg twice daily was statistically superior to placebo on the PANSS total score (Trial 1 in <a href="#t13">Table 13</a>).
</p>
<p>In trial 2, a 6-week trial (n=448), comparing two fixed doses of SAPHRIS (5 mg and 10 mg twice daily) to placebo, SAPHRIS 5 mg twice daily was statistically superior to placebo on the PANSS total score. SAPHRIS 10 mg twice daily showed no added benefit compared to 5 mg twice daily and was not significantly different from placebo (Trial 2 in <a href="#t14">Table 14</a>).
</p>
<p>An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, sex or race.
</p>
<a name="t13"></a><table width="100%">
<caption><span>Table 13: Adult <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> Trials Establishing Efficacy
</span></caption>
<col align="left" width="12.460%">
<col align="left" width="28.140%">
<col align="left" width="19.780%">
<col align="left" width="19.780%">
<col align="left" width="19.840%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote">SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, not adjusted for multiple comparisons.
</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> Difference (drug minus placebo) in least-squares mean change from baseline.
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">* Doses that are demonstrated to be effective.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="middle"><span class="Bold">Trial Number</span></td>
<td class="Toprule" align="left" valign="middle"><span class="Bold">Treatment Group</span></td>
<td class="Botrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">Primary Efficacy Measure: PANSS Total Score</span></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Mean Baseline Score (SD)</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">LS Mean Change from Baseline (SE)</span></td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">Placebo-subtracted Difference</span><span class="Bold"><span class="Sup">a
</span></span><span class="Bold">(95% CI)</span>
</td>
</tr>
<tr>
<td align="left" valign="middle">Trial 1
</td>
<td align="left" valign="middle">SAPHRIS 5 mg* twice daily
</td>
<td align="center" valign="middle">96.5 (16.4)
</td>
<td align="center" valign="middle">-14.4 (2.6)
</td>
<td align="center" valign="middle">-9.7 (-17.6, -1.8)
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle">Placebo
</td>
<td class="Botrule" align="center" valign="middle">92.4 (14.9)
</td>
<td class="Botrule" align="center" valign="middle">-4.6 (2.5)
</td>
<td class="Botrule" align="center" valign="middle">--
</td>
</tr>
<tr>
<td align="left" valign="middle">Trial 2
</td>
<td align="left" valign="middle">SAPHRIS 5 mg* twice daily
</td>
<td align="center" valign="middle">89.2 (12.0)
</td>
<td align="center" valign="middle">-16.2 (1.7)
</td>
<td align="center" valign="middle">-5.5 (-10.7, -0.2)
</td>
</tr>
<tr>
<td align="left" valign="middle"></td>
<td align="left" valign="middle">SAPHRIS 10 mg twice daily
</td>
<td align="center" valign="middle">89.1 (12.9)
</td>
<td align="center" valign="middle">-14.9 (1.7)
</td>
<td align="center" valign="middle">-4.1 (-9.4, 1.2)
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle">Placebo
</td>
<td class="Botrule" align="center" valign="middle">88.9 (11.7)
</td>
<td class="Botrule" align="center" valign="middle">-10.7 (1.6)
</td>
<td class="Botrule" align="center" valign="middle">--
</td>
</tr>
</tbody>
</table>
<p>Maintenance of efficacy has been demonstrated in a placebo-controlled, double-blind, multicenter, flexible dose (5 mg or 10 mg twice daily based on tolerability) clinical trial with a randomized withdrawal design (Study 3). All patients were initially administered 5 mg twice daily for 1 week and then titrated up to 10 mg twice daily. A total of 700 patients entered open-label treatment with SAPHRIS for a period of 26 weeks. Of these, a total of 386 patients who met pre-specified criteria for continued stability (mean length of stabilization was 22 weeks) were randomized to a double-blind, placebo-controlled, randomized withdrawal phase. SAPHRIS was statistically superior to placebo in time to relapse or impending relapse defined as increase in PANSS â‰¥20% from baseline and a Clinical Global Impressionâ€“Severity of Illness (CGI-S) score â‰¥4 (at least 2 days within 1 week) or PANSS score â‰¥5 on â€œhostilityâ€? or â€œuncooperativenessâ€? items and CGI-S score â‰¥4 (â‰¥2 days within a week), or PANSS score â‰¥5 on any two of the following items: â€œunusual thought content,â€? â€œconceptual disorganization,â€? or â€œhallucinatory behaviorâ€? items, and CGI-S score â‰¥4 (â‰¥2 days within 1 week) or investigator judgment of worsening symptoms or increased risk of violence to self (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>) or other persons. The Kaplan-Meier curves of the time to relapse or impending relapse during the double-blind, placebo-controlled, randomized withdrawal phase of this trial for SAPHRIS and placebo are shown in <a href="#fig4">Figure 4</a>.<br><br></p>
<p class="MultiMediaCaption"><a name="fig4"></a><span class="Bold">Figure 4: Kaplan-Meier Estimation of Percent Relapse/Impending Relapse for SAPRHRIS and placebo</span></p>
<div class="Figure">
<a name="f05"></a><img alt="Figure 4
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s109"></a><a name="section-14.2"></a><p></p>
<h2>14.2 Bipolar Disorder
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s110"></a><a name="section-14.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Monotherapy</span></p>
<p><span class="Italics">Adults</span>: The efficacy of SAPHRIS in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> was established in two similarly designed 3-week, randomized, double-blind, placebo-controlled, and active-controlled (olanzapine) trials of adult patients who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> with an acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features.
</p>
<p>The primary rating instrument used for assessing <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms in these trials was the Young <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Rating Scale (YMRS), an 11-item clinician-rated scale traditionally used to assess the degree of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptomatology in a range from 0 (no <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> features) to 60 (maximum score). Patients were also assessed on the Clinical Global Impression â€“ Bipolar (CGI-BP) scale. In both trials, all patients randomized to SAPHRIS were initially administered 10 mg twice daily, and the dose could be adjusted within the dose range of 5 to 10 mg twice daily from Day 2 onward based on efficacy and tolerability. Ninety percent of patients remained on the 10 mg twice daily dose. SAPHRIS was statistically superior to placebo on the YMRS total score and the CGI-BP Severity of Illness score (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>) in both studies (Trials 1 and 2 in <a href="#t14">Table 14</a>).
</p>
<p>An examination of subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, sex, or race.
</p>
<p><span class="Italics">Pediatric patients:</span> The efficacy of SAPHRIS in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> was established in a single, 3-week, placebo-controlled, double-blind trial of 403 pediatric patients 10 to 17 years of age, of whom 302 patients received SAPHRIS at fixed doses of 2.5 mg, 5 mg and 10 mg twice daily. All patients were started on 2.5 mg twice daily.Â  For those assigned to 5 mg twice daily, the dose was increased to 5 mg twice daily after 3 days.Â  For those assigned to 10 mg twice daily, the dose was increased from 2.5 to 5 mg twice daily after 3 days, and then to 10 mg twice daily after 3 additional days.
</p>
<p>SAPHRIS was statistically superior to placebo in improving YMRS total score and the CGI-BP Severity of Illness score (overall) as measured by the change from baseline to week 3 (Trial 3 Pediatric in <a href="#t14">Table 14</a>). An examination of subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, sex, and race.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s111"></a><a name="section-14.2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Adjunctive Therapy:</span> The efficacy of SAPHRIS as an adjunctive therapy in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> was established in a 12-week, placebo-controlled trial with a 3-week primary efficacy endpoint involving 326 adult patients with a <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>, with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features, who were partially responsive to lithium or valproate monotherapy after at least 2 weeks of treatment. All patients randomized to SAPHRIS were initially administered 5 mg twice daily, and the dose could be adjusted within the dose range of 5 to 10 mg twice daily from Day 2 onward based on efficacy and tolerability. SAPHRIS was statistically superior to placebo in the reduction of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms (measured by the YMRS total score) as an adjunctive therapy to lithium or valproate monotherapy at Week 3 (Trial 4 Adjunctive in <a href="#t14">Table 14</a>).
</p>
<a name="t14"></a><table width="100%">
<caption><span>Table 14: Bipolar Trials
</span></caption>
<col align="left" width="16.900%">
<col align="left" width="28.140%">
<col align="left" width="16.860%">
<col align="left" width="18.520%">
<col align="left" width="19.580%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote">SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, not adjusted for multiple comparisons.
</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> Difference (drug minus placebo) in least-squares mean change from baseline.
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">* Doses that are demonstrated to be effective.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" rowspan="2" valign="top"><span class="Bold">Study Number</span></td>
<td class="Toprule" align="left" valign="middle"><span class="Bold">Treatment Group</span></td>
<td class="Botrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">Primary Efficacy Measure: YMRS Total Score</span></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Mean Baseline Score (SD)</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">LS Mean Change from Baseline (SE)</span></td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">Placebo-subtracted Difference</span><span class="Bold"><span class="Sup">a
</span></span><span class="Bold">(95% CI)</span>
</td>
</tr>
<tr>
<td align="left" valign="middle">Trial 1
</td>
<td align="left" valign="middle">SAPHRIS 5-10 mg* twice daily
</td>
<td align="center" valign="middle">29.4 (6.7)
</td>
<td align="center" valign="middle">-11.5 (0.8)
</td>
<td align="center" valign="middle">-3.7 (-6.6, -0.7)
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle">Placebo
</td>
<td class="Botrule" align="center" valign="middle">28.3 (6.3)
</td>
<td class="Botrule" align="center" valign="middle">-7.8 (1.1)
</td>
<td class="Botrule" align="center" valign="middle">--
</td>
</tr>
<tr>
<td align="left" valign="middle">Trial 2
</td>
<td align="left" valign="middle">SAPHRIS 5-10 mg* twice daily
</td>
<td align="center" valign="middle">28.3 (5.5)
</td>
<td align="center" valign="middle">-10.8 (0.8)
</td>
<td align="center" valign="middle">-5.3 (-8.0, -2.5)
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle">Placebo
</td>
<td class="Botrule" align="center" valign="middle">29.0 (6.1)
</td>
<td class="Botrule" align="center" valign="middle">-5.5 (1.0)
</td>
<td class="Botrule" align="center" valign="middle">--
</td>
</tr>
<tr>
<td class="Botrule" align="left" rowspan="4" valign="top">Trial 3<br>(Pediatric<br>10 to17 years)
</td>
<td align="left" valign="middle">SAPHRIS 2.5 mg* twice daily
</td>
<td align="center" valign="middle">29.5 (5.7)
</td>
<td align="center" valign="middle">-12.8 (0.8)
</td>
<td align="center" valign="middle">-3.2 (-5.6, -0.8)
</td>
</tr>
<tr>
<td align="left" valign="middle">SAPHRIS 5 mg* twice daily
</td>
<td align="center" valign="middle">30.4 (5.9)
</td>
<td align="center" valign="middle">-14.9 (0.8)
</td>
<td align="center" valign="middle">-5.3 (-7.7, -2.9)
</td>
</tr>
<tr>
<td align="left" valign="middle">SAPHRIS 10 mg* twice daily
</td>
<td align="center" valign="middle">30.1 (5.7)
</td>
<td align="center" valign="middle">-15.8 (0.9)
</td>
<td align="center" valign="middle">-6.2 (-8.6, -3.8)
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Placebo
</td>
<td class="Botrule" align="center" valign="middle">30.1 (5.7)
</td>
<td class="Botrule" align="center" valign="middle">- 9.6 (0.9)
</td>
<td class="Botrule" align="center" valign="middle">--
</td>
</tr>
<tr>
<td align="left" valign="top">Trial 4 (Adjunctive)
</td>
<td align="left" valign="middle">SAPHRIS 5-10 mg* twice daily + lithium/ Valproate
</td>
<td align="center" valign="middle">28.0 (5.6)<br>
</td>
<td align="center" valign="middle">-10.3 (0.8)<br>
</td>
<td align="center" valign="middle">-2.4 (-4.4, -0.3)<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle">Lithium/Valproate
</td>
<td class="Botrule" align="center" valign="middle">28.2 (5.8)
</td>
<td class="Botrule" align="center" valign="middle">-7.9 (0.8)
</td>
<td class="Botrule" align="center" valign="middle">--
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s112"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">SAPHRIS (asenapine) sublingual tablets are supplied as:
</p>
<p><span class="Bold">2.5 mg Tablets, black cherry flavor</span></p>
<p>Round, white to off-white sublingual tablets, with a hexagon on one side.
</p>
<table width="100%">
<col align="left" width="15.000%">
<col align="left" width="30.000%">
<col align="left" width="55.000%">
<tbody class="Headless">
<tr class="First"><td align="justify" colspan="3" valign="top">Child-resistant packaging
</td></tr>
<tr>
<td align="justify" valign="top">Â  Â  Â  Â Box of 60
</td>
<td align="justify" valign="top">6 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets
</td>
<td align="justify" valign="top">NDC 0456-2402-60
</td>
</tr>
<tr>
<td align="justify" colspan="2" valign="top">Hospital Unit Dose
</td>
<td align="justify" valign="top"></td>
</tr>
<tr>
<td align="justify" valign="top">Â  Â  Â  Â Box of 100
</td>
<td align="justify" valign="top">10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets
</td>
<td align="justify" valign="top">NDC 0456-2402-63
</td>
</tr>
<tr><td align="justify" colspan="3" valign="top"><span class="Bold">5 mg Tablets, black cherry flavor</span></td></tr>
<tr><td align="justify" colspan="3" valign="top">Round, white to off-white sublingual tablets, with â€œ5â€? on one side within a circle.
</td></tr>
<tr><td align="justify" colspan="3" valign="top">Child-resistant packaging
</td></tr>
<tr>
<td align="justify" valign="top">Â  Â  Â  Â Box of 60
</td>
<td align="justify" valign="top">6 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets
</td>
<td align="justify" valign="top">NDC 0456-2405-60
</td>
</tr>
<tr><td align="justify" colspan="3" valign="top">Hospital Unit Dose
</td></tr>
<tr>
<td align="justify" valign="top">Â  Â  Â  Â Box of 100
</td>
<td align="justify" valign="top">10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets
</td>
<td align="justify" valign="top">NDC 0456-2405-63
</td>
</tr>
<tr><td align="justify" colspan="3" valign="top"><span class="Bold">10 mg Tablets, black cherry flavor</span></td></tr>
<tr><td align="justify" colspan="3" valign="top">Round, white to off-white sublingual tablets, with â€œ10â€? on one side within a circle.
</td></tr>
<tr><td align="justify" colspan="3" valign="top">Child-resistant packaging
</td></tr>
<tr>
<td align="justify" valign="top">Â  Â  Â  Â Box of 60
</td>
<td align="justify" valign="top">6 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets
</td>
<td align="justify" valign="top">NDC 0456-2410-60
</td>
</tr>
<tr><td align="justify" colspan="3" valign="top">Hospital Unit Dose
</td></tr>
<tr class="Last">
<td align="justify" valign="top">Â  Â  Â  Â Box of 100
</td>
<td align="justify" valign="top">10 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with 10 tablets
</td>
<td align="justify" valign="top">NDC 0456-2410-63
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="s113"></a><a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p><span class="Bold">Store at 15Â°C to 30Â°C (59Â°F to 86Â°F) [see USP Controlled Room Temperature].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s114"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s115"></a><a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">Dosage and Administration</span></p>
<p>Counsel patients on proper sublingual administration of SAPHRIS and advise them to read the FDA-approved patient labeling (Instructions for Use). When initiating treatment with SAPHRIS, provide dosage escalation instructions <span class="Italics">[see Dosage and Administration (<a href="#s5">2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s116"></a><a name="section-16.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>Counsel patients on the signs and symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, tongue or throat, feeling lightheaded etc.) and to seek immediate emergency assistance if they develop any of these signs and symptoms <span class="Italics">[see Contraindications (<a href="#s14">4</a>), Warnings and Precautions (<a href="#s27">5.6</a>) and Adverse Reactions (<a href="#s38">6</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s117"></a><a name="section-16.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reactions</span></span></p>
<p>Inform patients that <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>, primarily in the sublingual area, including oral <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>/<span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> have been reported. Instruct patients to monitor for these reactions <span class="Italics">[see Adverse Reactions (<a href="#s62">6.2</a>)].</span>  Inform patients that <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the mouth or throat may occur directly after administration of SAPHRIS and usually resolves within 1 hour <span class="Italics">(see Adverse reactions (<a href="#s39">6.1</a>))</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s118"></a><a name="section-16.4"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></span></p>
<p>Counsel patients about a potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) that has been reported in association with administration of antipsychotic drugs. Patients should contact their health care provider or report to the emergency room if they experience the following signs and symptoms of NMS, including <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia) <span class="Italics">[see Warnings and Precautions (<a href="#s18">5.3</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s119"></a><a name="section-16.5"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></span></p>
<p>Counsel patients on the signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and to contact their health care provider if these abnormal movements occur [<span class="Italics">see Warnings and Precautions (</span>5.4<span class="Italics">)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s120"></a><a name="section-16.6"></a><p></p>
<p class="First"><span class="Bold">Metabolic Changes (</span><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>)
</p>
<p>Educate patients about the risk of metabolic changes, how to recognize symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (high blood sugar) and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and the need for specific monitoring, including blood glucose, lipids, and weight <span class="Italics">[see Warnings and Precautions (<a href="#s20">5.5</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s121"></a><a name="section-16.7"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></span></p>
<p> Educate patients about the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (symptoms include feeling dizzy or lightheaded upon standing) especially early in treatment, and also at times of re-initiating treatment or increases in dose <span class="Italics">[see Warnings and Precautions (<a href="#s28">5.7</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s122"></a><a name="section-16.8"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></p>
<p>Advise patients with a pre-existing low WBC or a history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> they should have their CBC monitored while taking SAPHRIS <span class="Italics">[see Warnings and Precautions (<a href="#s29">5.8</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s123"></a><a name="section-16.9"></a><p></p>
<p class="First"><span class="Bold">Interference with Cognitive and Motor Performance</span></p>
<p>Caution patients about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that SAPHRIS therapy does not affect them adversely <span class="Italics">[see Warnings and Precautions (<a href="#s33">5.12</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s124"></a><a name="section-16.10"></a><p></p>
<p class="First"><span class="Bold">Heat Exposure and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></span></p>
<p>Counsel patients regarding appropriate care in avoiding overheating and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> <span class="Italics">[see Warnings and Precautions (<a href="#s34">5.13</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s125"></a><a name="section-16.11"></a><p></p>
<p class="First"><span class="Bold">Concomitant Medications</span></p>
<p>Advise patients to inform their health care provider if they are taking, or plan to take, any prescription or over-the-counter medications since there is a potential for interactions <span class="Italics">[see Drug Interactions (<a href="#s64">7.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s126"></a><a name="section-16.12"></a><p></p>
<p class="First"><span class="Bold">Pregnancy</span></p>
<p> Advise patients that SAPHRIS may cause fetal harm as well as extrapyramidal and/or withdrawal symptoms in a neonate.  Advise patients to notify their healthcare provider with a known or suspected pregnancy <span class="Italics">[see Use in Specific Populations (<a href="#s67">8.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s127"></a><a name="section-16.13"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Registry</span></p>
<p>Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to SAPHRIS during pregnancy <span class="Italics">[see Use in Specific Populations (<a href="#s67">8.1</a>)]</span>.
</p>
<p>Manufactured by: Catalent UK Swindon Zydis Ltd., Blagrove, Swindon, Wiltshire, SN5 8RU, UK
</p>
<p>Distributed by<br>Forest Pharmaceuticals, Inc. <br>Subsidiary of Forest Laboratories, LLC. <br>Cincinnati, OH 45209
</p>
<p>U.S. Patent Nos. 5,763,476 and 7,741,358.
</p>
<p>Â© 2013 Merck Sharp &amp; Dohme B. V.; used by. Actavis, Inc. or its affiliates under license.<br>Â© 2015 Actavis.  All rights reserved.<br>The trademark SAPHRIS is used by Actavis, Inc. or its affiliates under license from Merck Sharp &amp; Dohme B.V.
</p>
</div>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="s128"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">INSTRUCTIONS FOR USE</span></p>
<p>SAPHRISÂ® (asenapine)
</p>
<p>sublingual tablets
</p>
<p>Read these Instructions for Use before you start using SAPHRIS and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment.
</p>
<p><span class="Bold">IMPORTANT:</span></p>
<ul class="Disc">
<li><span class="Bold">For sublingual (under your tongue) use only</span></li>
<li><span class="Bold">Do not remove tablet until ready to administer.</span></li>
<li><span class="Bold">Use dry hands when handling tablet.</span></li>
</ul>
<p><span class="Bold">Your SAPHRIS tablets</span></p>
<div class="Figure">
<a name="f06"></a><img alt="Figure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-06.jpg">
</div>
<p><span class="Bold">Directions for Taking your SAPHRIS Tablets:</span></p>
<p><span class="Bold">Step 1.</span> Firmly press and hold thumb button, then pull out the tablet pack (see <a href="#f07">Figure A</a>). <span class="Bold">Do not push tablet through the tablet pack. Do not cut or tear the tablet pack.</span></p>
<div class="Figure">
<a name="f07"></a><img alt="Figure A
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-07.jpg"><p class="MultiMediaCaption">Figure A
</p>
</div>
<p><span class="Bold">Step 2.</span> Peel back the colored tab (see <a href="#f08">Figure B</a>).
</p>
<div class="Figure">
<a name="f08"></a><img alt="Figure B
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-08.jpg"><p class="MultiMediaCaption">Figure B
</p>
</div>
<p><span class="Bold">Step 3.</span> Gently remove the tablet (see <a href="#f09">Figure C</a>). <span class="Bold">Do not split, cut or crush the tablet.</span></p>
<div class="Figure">
<a name="f09"></a><img alt="Figure C
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-09.jpg"><p class="MultiMediaCaption">Figure C
</p>
</div>
<p><span class="Bold">Step 4.</span> Place the <span class="Bold">whole</span> tablet <span class="Bold">under</span> tongue and allow it to dissolve completely (see <a href="#f10">Figure D</a>).
</p>
<div class="Figure">
<a name="f10"></a><img alt="Figure D
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-10.jpg"><p class="MultiMediaCaption">Figure D
</p>
</div>
<p><span class="Bold">Do not chew or swallow the tablet.</span></p>
<p><span class="Bold">Do not eat or drink for 10 minutes</span> (See <a href="#f11">Figure E</a>).
</p>
<div class="Figure">
<a name="f11"></a><img alt="Figure E
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-11.jpg"><p class="MultiMediaCaption">Figure E
</p>
</div>
<p><span class="Bold">Step 5.</span> Slide the tablet pack back into case until it clicks (see <a href="#f12">Figure F</a>).
</p>
<div class="Figure">
<a name="f12"></a><img alt="Figure F
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-12.jpg"><p class="MultiMediaCaption">Figure F
</p>
</div>
<p><span class="Bold">Storing SAPHRIS tablets:</span></p>
<p>Store SAPHRIS tablets at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).
</p>
<p>These Instructions for Use have been approved by the U.S. Food and Drug Administration.
</p>
<p>Manufactured by: Catalent UK Swindon Zydis Ltd., Blagrove, Swindon, Wiltshire, SN5 8RU, UK<br>Distributed by: Forest Pharmaceuticals, Inc., Subsidiary of Forest Laboratories, LLC, St. Louis, MO 63045, USA<br>U.S. Patent Nos. 5,763,476 and 7,741,358.<br>Â© 2013 Merck Sharp &amp; Dohme B. V.; used by Actavis, Inc. or its affiliates under license.<br>Â© 2015 Actavis.  All rights reserved.<br>The trademark SAPHRIS is used by Actavis, Inc. or its affiliates under license from Merck Sharp &amp; Dohme B.V.
</p>
<p>Revised: March 2015
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s129"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - 2.5 mg 60 Count <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Label</span></p>
<p>NDC 0456-2402-06
</p>
<p><span class="Bold">Rx only</span></p>
<p>10 Tablets
</p>
<p><span class="Bold">Saphris</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">2.5 mg</span></p>
<p>(asenapine) sublingual tablets
</p>
<p><span class="Bold">Black Cherry</span><br>Flavor
</p>
<div class="Figure">
<a name="f13"></a><img alt="Principal Display Panel - 2.5 mg 60 Count <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-13.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s130"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - 2.5 mg 60 Count Carton Label</span></p>
<p>Rx only
</p>
<p>NDC 0456-2402-60
</p>
<p><span class="Bold">Saphris</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold">2.5 mg</span></p>
<p>(asenapine) sublinhual tablets
</p>
<p><span class="Bold">For sublingual use only.</span></p>
<p><span class="Bold">Do not split, cut, or crush tablet.</span></p>
<p><span class="Bold">Do not chew or swallow tablet.</span></p>
<p><span class="Bold">Fragile: Do not push tablet through<br>tablet pack</span></p>
<p>60 Tablets
</p>
<p><span class="Bold">Black Cherry</span><br>Flavor
</p>
<div class="Figure">
<a name="f14"></a><img alt="Principal Display Panel - 2.5 mg 60 Count Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-14.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s131"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - 5 mg 60 count Carton Label</span></p>
<p><span class="Bold">Rx only</span></p>
<p>NDC 0456-2405-60
</p>
<p><span class="Bold">Saphris</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">5mg</span></p>
<p>(asenapine) sublingual tablets
</p>
<p><span class="Bold">For sublingual use only.</span></p>
<p><span class="Bold">Do not split, cut, or crush tablet.</span></p>
<p><span class="Bold">Do not chew or swallow tablet.</span></p>
<p><span class="Bold">Fragile: Do not push tablet through<br>tablet pack.</span></p>
<p><span class="Bold">60 Tablets</span></p>
<p><span class="Bold">Black Cherry<br>Flavor</span></p>
<div class="Figure">
<a name="f15"></a><img alt="Principal Display Panel - 5 mg 60 count Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-15.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s132"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - 10 mg 60 count Carton Label</span></p>
<p><span class="Bold">Rx only</span></p>
<p>NDC 0456-2410-60
</p>
<p><span class="Bold">Saphris</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">10mg</span></p>
<p>(asenapine) sublingual tablets
</p>
<p><span class="Bold">For sublingual use only.</span></p>
<p><span class="Bold">Do not split, cut, or crush tablet.</span></p>
<p><span class="Bold">Do not chew or swallow tablet.</span></p>
<p><span class="Bold">Fragile: Do not push tablet through<br>tablet pack.</span></p>
<p><span class="Bold">60 Tablets</span></p>
<p><span class="Bold">Black Cherry<br>Flavor</span></p>
<div class="Figure">
<a name="f16"></a><img alt="Principal Display Panel - 10 mg 60 count Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-16.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s133"></a><a name="section-22"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - 5 mg Hospital Unit Dose</span></p>
<p><span class="Bold">Saphris</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">5mg</span></p>
<p>(asenapine) sublingual tablets
</p>
<p><span class="Bold">Rx only</span></p>
<p>NDC 0456-2405-63
</p>
<p><span class="Bold">Saphiris</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">5mg</span></p>
<p>(asenapine) sublingual tablets
</p>
<p><span class="Bold">For sublingual use only.</span></p>
<p><span class="Bold">Do not split, cut, or crush tablet.</span></p>
<p><span class="Bold">Do not chew or swallow tablet.</span></p>
<p><span class="Bold">Fragile: Do not push tablet through<br>tablet pack.</span></p>
<p><span class="Bold">Black Cherry<br>Flavor</span></p>
<p><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">HOSPITAL UNIT DOSE</span></p>
<div class="Figure">
<a name="f17"></a><img alt="Principal Display Panel - 5 mg Hospital Unit Dose
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-17.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s134"></a><a name="section-23"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - 10 mg Hospital Unit Dose</span></p>
<p><span class="Bold">Saphris</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">10mg</span></p>
<p>(asenapine) sublingual tablets
</p>
<p><span class="Bold">Rx only</span></p>
<p>NDC 0456-2410-63
</p>
<p><span class="Bold">Saphiris</span><span class="Bold"><span class="Sup">Â®</span></span><span class="Bold">10mg</span></p>
<p>(asenapine) sublingual tablets
</p>
<p><span class="Bold">For sublingual use only.</span></p>
<p><span class="Bold">Do not split, cut, or crush tablet.</span></p>
<p><span class="Bold">Do not chew or swallow tablet.</span></p>
<p><span class="Bold">Fragile: Do not push tablet through<br>tablet pack.</span></p>
<p><span class="Bold">Black Cherry<br>Flavor</span></p>
<p><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">HOSPITAL UNIT DOSE</span></p>
<div class="Figure">
<a name="f18"></a><img alt="Principal Display Panel - 10 mg Hospital Unit Dose
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&amp;name=sap01-0007-18.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SAPHRISÂ 		
					</strong><br><span class="contentTableReg">asenapine maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0456-2402</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Asenapine Maleate</strong> (Asenapine) </td>
<td class="formItem">Asenapine</td>
<td class="formItem">2.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white- to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY (CHERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2;5;hexagon
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0456-2402-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0456-2402-60</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0456-2402-11</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0456-2402-63</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022117</td>
<td class="formItem">12/30/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SAPHRISÂ 		
					</strong><br><span class="contentTableReg">asenapine maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0456-2405</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Asenapine Maleate</strong> (Asenapine) </td>
<td class="formItem">Asenapine</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white- to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY (CHERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">5
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0456-2405-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0456-2405-60</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0456-2405-11</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0456-2405-63</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022117</td>
<td class="formItem">09/30/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SAPHRISÂ 		
					</strong><br><span class="contentTableReg">asenapine maleate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0456-2410</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Asenapine Maleate</strong> (Asenapine) </td>
<td class="formItem">Asenapine</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white- to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY (CHERRY) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0456-2410-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0456-2410-60</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0456-2410-11</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0456-2410-63</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022117</td>
<td class="formItem">09/30/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Forest Laboratories, Inc.
							(001288281)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aspen Oss B.V.</td>
<td class="formItem"></td>
<td class="formItem">491013870</td>
<td class="formItem">ANALYSIS(0456-2402, 0456-2405, 0456-2410)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aspen Oss B.V..</td>
<td class="formItem"></td>
<td class="formItem">491017488</td>
<td class="formItem">API MANUFACTURE(0456-2402, 0456-2405, 0456-2410)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions Limited</td>
<td class="formItem"></td>
<td class="formItem">237676320</td>
<td class="formItem">MANUFACTURE(0456-2402, 0456-2405, 0456-2410), PACK(0456-2402, 0456-2405, 0456-2410)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Organon (Ireland) Limited</td>
<td class="formItem"></td>
<td class="formItem">219542271</td>
<td class="formItem">PACK(0456-2402, 0456-2405, 0456-2410)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>91a47034-3e28-41ba-8dcb-f05e9be2c929</div>
<div>Set id: 5429f134-839f-4ffc-9944-55f51238def8</div>
<div>Version: 5</div>
<div>Effective Time: 20150319</div>
</div>
</div>Â <div class="DistributorName">Forest Laboratories, Inc.</div></p>
</body></html>
